PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 25385465-1 2014 A spectroscopic investigation of the complexes formed between the Pb(II) ion and D-penicillamine (H2Pen), a chelating agent used in the treatment of lead poisoning, was carried out on two sets of alkaline aqueous solutions with CPb(II) 10 and 100 mM, varying the H2Pen/Pb(II) molar ratio (2.0, 3.0, 4.0, 10.0). Penicillamine 81-96 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 100-103 25385465-7 2014 The combined spectroscopic results, reporting delta((207)Pb) 1870 ppm and lambdamax 298 nm for a Pb(II)S2NO site, are consistent with a dominating 1:2 lead(II):penicillamine complex with [Pb(S,N,O-Pen)(S-HnPen)](2-n) (n = 0-1) coordination in alkaline solutions, and provide useful structural information on how penicillamine can function as an antidote against lead toxicity in vivo. Penicillamine 164-177 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 201-204 25173990-9 2014 Both anti- and proconvulsant effects of D-pen were blocked by a single dose of a nonspecific inhibitor of nitric oxide synthase (NOS), L-NAME (10 mg/kg, i.p. Penicillamine 40-45 nitric oxide synthase 1, neuronal Mus musculus 106-127 24901380-8 2014 d-penicillamine revealed hepatic adaptive response and an improvement in hepatic function in Npc1(-/-) mice without any effect on neurological functions. Penicillamine 0-15 NPC intracellular cholesterol transporter 1 Mus musculus 93-97 32481987-3 2014 We find that QDs coated with zwitterionic d-penicillamine (DPA-QDs) or anionic mercaptosuccinic acid (MSA-QDs) bind to the same site of serum albumin, domain II A, site I, and the differences of the Stern-Volmer quenching constant KSV and the binding constant K are about sixfold and sevenfold after 4 h of mixing, respectively. Penicillamine 42-57 albumin Homo sapiens 142-149 24771069-7 2014 In the present study, we found that treatment of BN rats with a low doses of D-penicillamine (10 or 15 mg/day) resulted in a mild increases in glutamate dehydrogenase (GLDH) and sorbitol dehydrogenase (SDH) activities; however, this was not associated with histological changes. Penicillamine 77-92 sorbitol dehydrogenase Rattus norvegicus 178-200 24771069-7 2014 In the present study, we found that treatment of BN rats with a low doses of D-penicillamine (10 or 15 mg/day) resulted in a mild increases in glutamate dehydrogenase (GLDH) and sorbitol dehydrogenase (SDH) activities; however, this was not associated with histological changes. Penicillamine 77-92 sorbitol dehydrogenase Rattus norvegicus 202-205 24771069-8 2014 A higher dose of D-penicillamine (20 mg/day) resulted in 63% of the rats developing a skin rash, and these rats had elevated serum GLDH and SDH levels with histopathological changes characteristic of granulomatous hepatitis. Penicillamine 17-32 sorbitol dehydrogenase Rattus norvegicus 140-143 24766067-1 2014 New tripodal metal-chelating agents derived from nitrilotriacetic acid (NTA) and extended by three unnatural amino acids D-penicillamine (D-Pen) are presented. Penicillamine 121-136 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 140-143 24578342-3 2014 The Gi2-coupled delta-opioid receptor agonist d-penicillamine (2,5)-enkephalin (DPDPE) activated cSrc, stimulated tyrosine phosphorylation of Galphai2, and induced regulator of G protein signaling 12 (RGS12) association; all three events were blocked by PI 3-kinase (LY294002) and cSrc (PP2) inhibitors and by expression of the COOH-terminal sequence of GRK2-(495-689), a Gbetagamma-scavenging peptide. Penicillamine 46-61 SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens 97-101 24578342-3 2014 The Gi2-coupled delta-opioid receptor agonist d-penicillamine (2,5)-enkephalin (DPDPE) activated cSrc, stimulated tyrosine phosphorylation of Galphai2, and induced regulator of G protein signaling 12 (RGS12) association; all three events were blocked by PI 3-kinase (LY294002) and cSrc (PP2) inhibitors and by expression of the COOH-terminal sequence of GRK2-(495-689), a Gbetagamma-scavenging peptide. Penicillamine 46-61 regulator of G protein signaling 12 Homo sapiens 164-199 24578342-3 2014 The Gi2-coupled delta-opioid receptor agonist d-penicillamine (2,5)-enkephalin (DPDPE) activated cSrc, stimulated tyrosine phosphorylation of Galphai2, and induced regulator of G protein signaling 12 (RGS12) association; all three events were blocked by PI 3-kinase (LY294002) and cSrc (PP2) inhibitors and by expression of the COOH-terminal sequence of GRK2-(495-689), a Gbetagamma-scavenging peptide. Penicillamine 46-61 regulator of G protein signaling 12 Homo sapiens 201-206 24578342-3 2014 The Gi2-coupled delta-opioid receptor agonist d-penicillamine (2,5)-enkephalin (DPDPE) activated cSrc, stimulated tyrosine phosphorylation of Galphai2, and induced regulator of G protein signaling 12 (RGS12) association; all three events were blocked by PI 3-kinase (LY294002) and cSrc (PP2) inhibitors and by expression of the COOH-terminal sequence of GRK2-(495-689), a Gbetagamma-scavenging peptide. Penicillamine 46-61 SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens 281-285 24578342-3 2014 The Gi2-coupled delta-opioid receptor agonist d-penicillamine (2,5)-enkephalin (DPDPE) activated cSrc, stimulated tyrosine phosphorylation of Galphai2, and induced regulator of G protein signaling 12 (RGS12) association; all three events were blocked by PI 3-kinase (LY294002) and cSrc (PP2) inhibitors and by expression of the COOH-terminal sequence of GRK2-(495-689), a Gbetagamma-scavenging peptide. Penicillamine 46-61 neuropeptide Y receptor Y6 (pseudogene) Homo sapiens 287-290 24578342-3 2014 The Gi2-coupled delta-opioid receptor agonist d-penicillamine (2,5)-enkephalin (DPDPE) activated cSrc, stimulated tyrosine phosphorylation of Galphai2, and induced regulator of G protein signaling 12 (RGS12) association; all three events were blocked by PI 3-kinase (LY294002) and cSrc (PP2) inhibitors and by expression of the COOH-terminal sequence of GRK2-(495-689), a Gbetagamma-scavenging peptide. Penicillamine 46-61 G protein-coupled receptor kinase 2 Homo sapiens 354-358 23706196-5 2013 In phosphate buffer solution (PBS) of pH8.0, the oxidation current increased linearly with two concentration intervals of D-PA, one is 1.0 to 10.0 muM and, the other is 10.0 to 800.0 muM. Penicillamine 122-126 latexin Homo sapiens 147-150 23706196-5 2013 In phosphate buffer solution (PBS) of pH8.0, the oxidation current increased linearly with two concentration intervals of D-PA, one is 1.0 to 10.0 muM and, the other is 10.0 to 800.0 muM. Penicillamine 122-126 latexin Homo sapiens 183-186 23669644-8 2013 Moreover, copper chelator, D-penicillamine, suppressed APP dimerization and decreased extracellular release of Abeta. Penicillamine 27-42 amyloid beta precursor protein Homo sapiens 111-116 23261512-1 2013 The structure and stability of D-penicillamine-capped gold nanoparticles (d-Pen Au NPs) were studied using spectroscopic tools. Penicillamine 31-46 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 76-79 23635318-2 2013 The pristine protective ligand is racemic penicillamine (rac-Pen), and the products of the ligand exchange reactions include clusters containing both rac-Pen and L-DTT (partial exchange). Penicillamine 42-55 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 61-64 24025788-1 2013 We assessed the effects of D-penicillamine (D-PA) on cross-linkages in elastin and vaso-regulatory function in rats. Penicillamine 27-42 elastin Rattus norvegicus 71-78 23200399-4 2013 The chromatographic analysis of D-penicillamine was carried out on a C18 column using a mixture of acid phosphate buffer and methanol as the mobile phase. Penicillamine 32-47 Bardet-Biedl syndrome 9 Homo sapiens 69-72 23841333-4 2013 The coordination of Cd2+ with those groups was supported by the application of auxiliary molecules (D-penicillamine, glycine, cysteine and glutamic acid dipeptides, mercaptosuccinic acid and N-acetyl-L-cysteine). Penicillamine 100-115 CD2 molecule Homo sapiens 20-23 24025788-1 2013 We assessed the effects of D-penicillamine (D-PA) on cross-linkages in elastin and vaso-regulatory function in rats. Penicillamine 44-48 elastin Rattus norvegicus 71-78 24025788-4 2013 The content of cross-linkages in elastin, i.e. desmosine and isodesmosine, which gives elasticity to the aortic wall, was significantly reduced in the D-PA treated groups versus the control groups. Penicillamine 151-155 elastin Rattus norvegicus 33-40 24025788-6 2013 In addition, after 7 weeks of treatment with D-PA, the change between systolic blood pressure before and after sympathetic stimulation (Delta-SBP) by L-epinephrine was about 2.5-fold larger than that in the control group. Penicillamine 45-49 spermine binding protein Rattus norvegicus 142-145 24025788-8 2013 These findings demonstrated that D-PA disrupted elastic lamellae of the rat aorta by reduction of the cross-linkages in elastin and collagen, which caused dysfunction of vaso-regulation. Penicillamine 33-37 elastin Rattus norvegicus 120-127 22007676-4 2011 Penicillamine-derived analogues are also inactive, likely due to unfavorable steric interactions with the carbonyl of Ser 12 in TLR2. Penicillamine 0-13 toll like receptor 2 Homo sapiens 128-132 22843330-0 2012 D-Penicillamine targets metastatic melanoma cells with induction of the unfolded protein response (UPR) and Noxa (PMAIP1)-dependent mitochondrial apoptosis. Penicillamine 0-15 phorbol-12-myristate-13-acetate-induced protein 1 Homo sapiens 108-112 22843330-0 2012 D-Penicillamine targets metastatic melanoma cells with induction of the unfolded protein response (UPR) and Noxa (PMAIP1)-dependent mitochondrial apoptosis. Penicillamine 0-15 phorbol-12-myristate-13-acetate-induced protein 1 Homo sapiens 114-120 22683336-0 2012 Anti-MuSK- and anti-AChR-positive myasthenia gravis induced by d-penicillamine. Penicillamine 63-78 muscle associated receptor tyrosine kinase Homo sapiens 5-9 22683336-3 2012 In most patients with D-penicillamine-induced MG, anti-AChR antibodies are detected, but the presence of anti-MuSK antibodies has not been reported previously. Penicillamine 22-37 muscle associated receptor tyrosine kinase Homo sapiens 110-114 22683336-9 2012 CONCLUSION: D-penicillamine can cause anti-AChR and anti-MuSK antibody-positive MG, a rare phenomenon which is reversed after discontinuation of D-penicillamine treatment. Penicillamine 12-27 muscle associated receptor tyrosine kinase Homo sapiens 57-61 22683336-9 2012 CONCLUSION: D-penicillamine can cause anti-AChR and anti-MuSK antibody-positive MG, a rare phenomenon which is reversed after discontinuation of D-penicillamine treatment. Penicillamine 145-160 muscle associated receptor tyrosine kinase Homo sapiens 57-61 22629446-0 2012 Penicillamine increases free copper and enhances oxidative stress in the brain of toxic milk mice. Penicillamine 0-13 ATPase, Cu++ transporting, beta polypeptide Mus musculus 82-92 22629446-3 2012 The aim of this study was to determine how the copper metabolism changes and whether the change impairs the brain of toxic milk (tx) mice, an animal model of WD, during the PA administration. Penicillamine 173-175 ATPase, Cu++ transporting, beta polypeptide Mus musculus 117-127 22629446-10 2012 Intense staining of ATP7A in the choroid plexus was found in tx mice on the 3rd and 10th day of PA treatment, but rare staining of ATP7A and CTR1 in the blood-brain barrier (BBB). Penicillamine 96-98 ATPase, Cu++ transporting, alpha polypeptide Mus musculus 20-25 21098689-0 2011 D-penicillamine interferes with S-homocysteinylation and S-cysteinylation of LDL apolipoprotein B. Penicillamine 0-15 apolipoprotein B Homo sapiens 81-97 19575532-9 2009 Furthermore, treatment of a murine macrophage cell line, RAW264.7, with penicillamine increased the production of TNF-alpha, IL-6, and IL-23, providing additional evidence that penicillamine activates macrophages. Penicillamine 72-85 tumor necrosis factor Mus musculus 114-123 20617791-3 2010 As a result of the introduction of cyclic and topological constraints with penicillamines, 2 (Tyr-cyclo[d-Pen-Gly-Phe-Pen]-Pro-Leu-Trp-NH-[3",5"-(CF(3))(2)-Bzl]) was found as the best bifunctional compound with effective NK1 antagonist and potent opioid agonist activities, and 1400-fold delta-selectivity over the mu-receptor. Penicillamine 75-89 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 106-109 20617791-3 2010 As a result of the introduction of cyclic and topological constraints with penicillamines, 2 (Tyr-cyclo[d-Pen-Gly-Phe-Pen]-Pro-Leu-Trp-NH-[3",5"-(CF(3))(2)-Bzl]) was found as the best bifunctional compound with effective NK1 antagonist and potent opioid agonist activities, and 1400-fold delta-selectivity over the mu-receptor. Penicillamine 75-89 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 118-121 20198267-1 2010 Treatment of Cu(AcO)(2) with D-penicillamine or L-cysteine in the presence of 2,2"-bipyridine afforded dicopper(II) complexes with a bis(bidentate-N,O) disulfide ligand, the formation mechanism of which was discussed on the basis of Cu(II)-thiolate interaction affected by an auxiliary ligand. Penicillamine 29-44 kallikrein related peptidase 15 Homo sapiens 16-19 19722195-7 2010 The role of the ER stress pathway was further confirmed through the small interfering RNA (siRNA)-mediated knockdown of CHOP, which attenuated NAC and PEN-induced apoptosis. Penicillamine 151-154 DNA damage inducible transcript 3 Homo sapiens 120-124 19575532-9 2009 Furthermore, treatment of a murine macrophage cell line, RAW264.7, with penicillamine increased the production of TNF-alpha, IL-6, and IL-23, providing additional evidence that penicillamine activates macrophages. Penicillamine 72-85 interleukin 6 Mus musculus 125-129 19575532-9 2009 Furthermore, treatment of a murine macrophage cell line, RAW264.7, with penicillamine increased the production of TNF-alpha, IL-6, and IL-23, providing additional evidence that penicillamine activates macrophages. Penicillamine 72-85 interleukin 23, alpha subunit p19 Mus musculus 135-140 19575532-9 2009 Furthermore, treatment of a murine macrophage cell line, RAW264.7, with penicillamine increased the production of TNF-alpha, IL-6, and IL-23, providing additional evidence that penicillamine activates macrophages. Penicillamine 177-190 tumor necrosis factor Mus musculus 114-123 19575532-9 2009 Furthermore, treatment of a murine macrophage cell line, RAW264.7, with penicillamine increased the production of TNF-alpha, IL-6, and IL-23, providing additional evidence that penicillamine activates macrophages. Penicillamine 177-190 interleukin 6 Mus musculus 125-129 19575532-9 2009 Furthermore, treatment of a murine macrophage cell line, RAW264.7, with penicillamine increased the production of TNF-alpha, IL-6, and IL-23, providing additional evidence that penicillamine activates macrophages. Penicillamine 177-190 interleukin 23, alpha subunit p19 Mus musculus 135-140 19439561-6 2009 Adhesion assays showed that: 1) PEN-released spermatozoa promptly recovered adhesion after removal of the disulphide-reductant and could be released again in response to PEN; 2) conversely, a limited number of HEP-released spermatozoa was able to readhere to the oviductal epithelium and this ability was not affected by HEP removal. Penicillamine 32-35 presenilin enhancer, gamma-secretase subunit Bos taurus 170-176 19469490-3 2009 The corresponding cadmium(II)-penicillamine complexes showed slightly shorter Cd-S bonds, 2.50-2.53 A, but with the Cd-(N/O) bond distances in a similar wide range, 2.28-2.33 A. Penicillamine 30-43 CDP-diacylglycerol synthase 1 Homo sapiens 78-82 18567001-6 2008 Both PTU and D-penicillamine inhibited strongly tyrosinase activity and melanin production in melanoma cells (p < 0.05-0.001). Penicillamine 13-28 tyrosinase Homo sapiens 48-58 19014823-3 2008 D-penicillamine probably inhibited thyroperoxidase activity in utero in healthy infants and during childhood in patients with Wilson"s disease. Penicillamine 0-15 thyroid peroxidase Homo sapiens 35-50 18158765-5 2007 For this purpose, first D-penicillamine (D-PA) and diethylene triaminepentaacetic acid (DTPA) were used to label SST with (99m)Tc and then radiopharmaceutical potential of three (99m)Tc-labeled complexes, (99m)Tc-D-PA, (99m)Tc-D-PA-SST, and (99m)Tc-DTPA-SST, were compared with each other. Penicillamine 41-45 somatostatin Rattus norvegicus 113-116 18379995-9 2008 3NT loss and NO(3) (-) production that clearly cannot be attributed to PON-1 were impaired by D-penicillamine and phenylacetate, inhibitor, and substrate of PON-1, respectively, leading to speculate on the active site. Penicillamine 94-109 paraoxonase 1 Homo sapiens 71-76 18379995-9 2008 3NT loss and NO(3) (-) production that clearly cannot be attributed to PON-1 were impaired by D-penicillamine and phenylacetate, inhibitor, and substrate of PON-1, respectively, leading to speculate on the active site. Penicillamine 94-109 paraoxonase 1 Homo sapiens 157-162 18158765-5 2007 For this purpose, first D-penicillamine (D-PA) and diethylene triaminepentaacetic acid (DTPA) were used to label SST with (99m)Tc and then radiopharmaceutical potential of three (99m)Tc-labeled complexes, (99m)Tc-D-PA, (99m)Tc-D-PA-SST, and (99m)Tc-DTPA-SST, were compared with each other. Penicillamine 24-39 somatostatin Rattus norvegicus 113-116 17940647-1 2007 The complex formation between mercury(II) and penicillamine (H(2)Pen = 3,3"-dimethyl cysteine) in alkaline aqueous solutions (pH approximately 2) has been investigated with extended X-ray absorption fine structure (EXAFS) and 199Hg NMR spectroscopy. Penicillamine 46-59 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 65-68 17940647-1 2007 The complex formation between mercury(II) and penicillamine (H(2)Pen = 3,3"-dimethyl cysteine) in alkaline aqueous solutions (pH approximately 2) has been investigated with extended X-ray absorption fine structure (EXAFS) and 199Hg NMR spectroscopy. Penicillamine 71-93 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 65-68 17937667-2 2007 Derivatives with penicillamine (H-Pen), cyclohexylalanine (H-Cha), butylglycine (L-t-Bg), and norleucine (H-Nle) showed relatively high inhibitory activities against lipase. Penicillamine 17-30 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 34-37 17918925-1 2007 The antiarthritis drug D-penicillamine (D-PEN) catalyzes zinc(II) transfer from carboxypeptidase A to chelators such as thionein and EDTA at a rate constant up to 400-fold faster than the uncatalyzed release. Penicillamine 23-38 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 42-45 17620346-3 2007 The in vitro covalent binding was inhibited in the presence of beta-aminopropionitrile, D-penicillamine, and hydralazine, which suggested that the aldehyde group of allysine in human elastin was relevant to the covalent binding. Penicillamine 88-103 elastin Homo sapiens 183-190 17596531-5 2007 We have developed a new protocol with DP to validate our Slc7a9 knockout mouse model for the study of the therapeutic effect of drugs in the treatment of cystine lithiasis. Penicillamine 38-40 solute carrier family 7 (cationic amino acid transporter, y+ system), member 9 Mus musculus 57-63 16753063-6 2006 D-penicillamine proved to be most efficient in supporting the conversion of plasminogen to angiostatin in vitro. Penicillamine 0-15 plasminogen Mus musculus 91-102 17408612-8 2007 Removal of endogenous Zn2+ with penicillamine in hDAT increased transport values. Penicillamine 32-45 solute carrier family 6 member 3 Homo sapiens 49-53 17206942-9 2006 D--Penicillamine significantly decreased serum alanine aminotransferase activity (weighted mean difference -45 IU/L, 95% CI: -75 to -15, P < 0.05) and led to significantly more adverse events (RR 4.18, 95% CI: 1.38-12.69, P = 0.01). Penicillamine 0-16 glutamic--pyruvic transaminase Homo sapiens 47-71 17723765-0 2006 Penicillamine determination using a tyrosinase micro-rotating biosensor. Penicillamine 0-13 tyrosinase Homo sapiens 36-46 16753063-9 2006 RESULTS: Surprisingly, we found that despite the superior angiostatin generating capacity of D-penicillamine in vitro, both in vivo angiostatin generation and anti-tumour effects of tPA/D-penicillamine treatment were impaired compared to our previous studies with tPA and captopril. Penicillamine 93-108 plasminogen Mus musculus 58-69 16549536-5 2006 There was marked inhibition in erythrocyte enzymes, namely, hexokinase, total adenosine triphosphatase (ATPase), and glucose-6-phosphate dehydrogenase (G-6-PD) from WD patients compared with patients on penicillamine and healthy children, indicating altered erythrocyte metabolism during a hemolytic crisis. Penicillamine 203-216 glucose-6-phosphate dehydrogenase Homo sapiens 152-158 16393772-3 2005 RESULTS: Aurothiomalate, hydroxychloroquine, methotrexate and leflunomide inhibited IL-1beta-induced inducible NO synthase (iNOS) expression and NO production in immortalized H4 chondrocytes, while penicillamine and sulfasalazine had no effect. Penicillamine 198-211 interleukin 1 beta Homo sapiens 84-92 15657943-0 2006 Effect of D-penicillamine on rat lung elastin cross-linking during the perinatal period. Penicillamine 10-25 elastin Rattus norvegicus 38-45 15657943-1 2006 This study was designed to clarify the effects of D-penicillamine (DPA), a drug used for treatment of various pathological events, on lung elastin formation and maturation of the newborn in the perinatal period. Penicillamine 50-65 elastin Rattus norvegicus 139-146 15657943-1 2006 This study was designed to clarify the effects of D-penicillamine (DPA), a drug used for treatment of various pathological events, on lung elastin formation and maturation of the newborn in the perinatal period. Penicillamine 67-70 elastin Rattus norvegicus 139-146 15657943-10 2006 In conclusion, our results indicate that 400 mg kg(-1) day(-1) DPA, a dose that is used in the treatment of Wilson"s disease, rheumatoid arthritis and cystinuria, caused the retardation of newborn maturation, a decrease in DES-IDES cross-links and levels of lung elastin of offspring in the perinatal period. Penicillamine 63-66 elastin Rattus norvegicus 263-270 15657943-11 2006 Another conclusion to be drawn from this study is that even low levels of Cu depletion due to DPA administration induces a change in cross-linking in lung elastin during the perinatal period. Penicillamine 94-97 elastin Rattus norvegicus 155-162 16148116-4 2005 The antirheumatic drug D-Penicillamine, which may induce lupus-like side-effects, stimulated type 2 responses against TNP-OVA, characterized by the production of IL-4 and TNP-specific IgG1 and IgE. Penicillamine 23-38 interleukin 4 Mus musculus 162-166 16148116-4 2005 The antirheumatic drug D-Penicillamine, which may induce lupus-like side-effects, stimulated type 2 responses against TNP-OVA, characterized by the production of IL-4 and TNP-specific IgG1 and IgE. Penicillamine 23-38 LOC105243590 Mus musculus 184-188 16148116-6 2005 Anti-CTLA-4 intensively enhanced the D-Penicillamine-induced effects. Penicillamine 37-52 cytotoxic T-lymphocyte-associated protein 4 Mus musculus 5-11 15663502-0 2005 Decline of anti-desmoglein 1 IgG ELISA scores by withdrawal of D-penicillamine in drug-induced pemphigus foliaceus. Penicillamine 63-78 desmoglein 1 Homo sapiens 16-28 16023247-9 2005 The copper chelator D-penicillamine inhibits Loxl2 induced oxidation of collagen but the Lox inhibitor beta-aminopropionitrile did not inhibit the oxidation using a BAPN concentration at which Lox activity was completely inhibited. Penicillamine 20-35 lysyl oxidase like 2 Homo sapiens 45-50 16023247-9 2005 The copper chelator D-penicillamine inhibits Loxl2 induced oxidation of collagen but the Lox inhibitor beta-aminopropionitrile did not inhibit the oxidation using a BAPN concentration at which Lox activity was completely inhibited. Penicillamine 20-35 lysyl oxidase Homo sapiens 45-48 15936165-0 2005 In situ generation of Co(II) by use of a solid-phase reactor in an FIA assembly for the spectrophotometric determination of penicillamine. Penicillamine 124-137 mitochondrially encoded cytochrome c oxidase II Homo sapiens 22-27 15936165-2 2005 The manifold includes a solid-phase reactor for the in situ production of the derivatizing reagent, Co(II) ion, which forms a coloured complex with penicillamine in an alkaline medium. Penicillamine 148-161 mitochondrially encoded cytochrome c oxidase II Homo sapiens 100-106 16007400-5 2005 Administration of D-penicillamine and restriction of dietary copper (<1 mg/day) were started, leading to a normalized serum alanine amino transferase (ALT) level. Penicillamine 18-33 glutamic--pyruvic transaminase Homo sapiens 124-149 16007400-5 2005 Administration of D-penicillamine and restriction of dietary copper (<1 mg/day) were started, leading to a normalized serum alanine amino transferase (ALT) level. Penicillamine 18-33 glutamic--pyruvic transaminase Homo sapiens 151-154 15604549-13 2005 DPA may interfere with elastin cross-linking through inhibition of the enzyme lysyl oxidase, or by formation of complexes with the cross-linked precursors, impairing a normal maturation of elastic fibers. Penicillamine 0-3 elastin Homo sapiens 23-30 15310212-1 2004 The S-bonded sulfenamide isomers have been prepared by the known reaction of hydroxylamine-O-sulfonate with (en)(2)Co(III) thiolate complexes of aminoethanethiol, cysteine, and penicillamine and the cis dithiolate formed by N,N"-ethylene-di-penicillamine (EDP) and Co(III). Penicillamine 177-190 mitochondrially encoded cytochrome c oxidase III Homo sapiens 118-121 20021081-4 2005 The treatments with D-penicillamine (D-PEN), ethylenediaminetetraacetic acid (EDTA), and MeOBGD reduced the content of Tb in the lung. Penicillamine 20-35 proprotein convertase subtilisin/kexin type 1 inhibitor Mus musculus 39-42 15448420-7 2004 RESULTS: Fifty-six of 87 patients (64%) given penicillamine normalized serum alanine aminotransferase (ALT) levels within a median of 17 months (range, 2 to 96 months). Penicillamine 46-59 glutamic--pyruvic transaminase Homo sapiens 77-101 15285646-0 2004 Comparison of cysteine and penicillamine ligands in a Co(II) maquette. Penicillamine 27-40 mitochondrially encoded cytochrome c oxidase II Homo sapiens 54-60 15764033-1 2004 A 63-year-old woman had D-penicillamine-induced pemphigus with a high index value of circulating autoantibodies against desmoglein 1. Penicillamine 24-39 desmoglein 1 Homo sapiens 120-132 12927381-0 2003 Modulation of D-penicillamine-induced autoimmunity in the Brown Norway rat using pharmacological agents that interfere with arachidonic acid metabolism or synthesis of inducible nitric oxide synthase. Penicillamine 14-29 nitric oxide synthase 2 Rattus norvegicus 168-199 14727922-5 2004 Low dose pretreatment also prevented the increase in IgE and IL-4 mRNA characteristic of the response to high dose D-penicillamine. Penicillamine 115-130 interleukin 4 Rattus norvegicus 61-65 14519758-3 2003 To determine the feasibility of copper-targeted therapy for prion disease, we treated mice with a copper chelator, D-(-)-penicillamine (D-PEN), starting immediately following intraperitoneal scrapie inoculation. Penicillamine 115-134 proprotein convertase subtilisin/kexin type 1 inhibitor Mus musculus 138-141 14598664-12 2003 MPO-ANCA is said to be related to pulmo-renal syndrome and is sometimes induced by D-penicillamine. Penicillamine 83-98 myeloperoxidase Homo sapiens 0-3 14626805-3 2003 Histologically, dermal elastin fibres were markedly reduced in the affected areas, consistent with penicillamine-induced elastolysis. Penicillamine 99-112 elastin Homo sapiens 23-30 14635094-5 2003 We have observed formation of dehydroalanine and dehydrovaline residues resulting from i, i+2-bridged cysteines and i, i+3-bridged cysteine/penicillamine peptides, respectively, thereby supporting a beta-elimination/Michael-addition mechanism for this transformation. Penicillamine 140-153 amyloid beta precursor protein Homo sapiens 197-203 18969150-6 2003 The HPLC method can also be modified to measure d-penicillamine (greater than 0.8 muM) in plasma (50 microl) providing a potential method to monitor plasma levels of this drug in patients. Penicillamine 48-63 latexin Homo sapiens 82-85 12645083-3 2003 The NO generators sodium nitroprusside (SNP) and S-nitroso-N-acetyl-D,L-penicillamine, in a dose-dependent manner, upregulated transcript levels of tyrosine hydroxylase, dopamine beta-hydroxylase, and phenylethanolamine N-methyltransferase, accompanied by long-term increases in their enzyme activities and the intracellular CA levels. Penicillamine 72-85 dopamine beta-hydroxylase Bos taurus 170-195 12645083-3 2003 The NO generators sodium nitroprusside (SNP) and S-nitroso-N-acetyl-D,L-penicillamine, in a dose-dependent manner, upregulated transcript levels of tyrosine hydroxylase, dopamine beta-hydroxylase, and phenylethanolamine N-methyltransferase, accompanied by long-term increases in their enzyme activities and the intracellular CA levels. Penicillamine 72-85 phenylethanolamine N-methyltransferase Bos taurus 201-239 12238917-2 2002 Conformational analysis of solution NMR data indicated that the putative biologically active conformation of U-II is stabilized by introduction of a Pen residue. Penicillamine 149-152 urotensin 2 Homo sapiens 109-113 12117417-4 2002 Oocytes expressing LAT1-4F2hc or LAT2-4F2hc demonstrated enhanced uptake of [(14)C]MeHg when administered as the L-cysteine or D,L-homocysteine complexes, but not when administered as the D-cysteine, N -acetyl-L-cysteine, penicillamine or GSH complexes. Penicillamine 222-235 solute carrier family 7 member 5 Homo sapiens 19-23 12117417-4 2002 Oocytes expressing LAT1-4F2hc or LAT2-4F2hc demonstrated enhanced uptake of [(14)C]MeHg when administered as the L-cysteine or D,L-homocysteine complexes, but not when administered as the D-cysteine, N -acetyl-L-cysteine, penicillamine or GSH complexes. Penicillamine 222-235 solute carrier family 3 member 2 Homo sapiens 24-29 12117417-4 2002 Oocytes expressing LAT1-4F2hc or LAT2-4F2hc demonstrated enhanced uptake of [(14)C]MeHg when administered as the L-cysteine or D,L-homocysteine complexes, but not when administered as the D-cysteine, N -acetyl-L-cysteine, penicillamine or GSH complexes. Penicillamine 222-235 linker for activation of T cells family member 2 Homo sapiens 33-37 12117417-4 2002 Oocytes expressing LAT1-4F2hc or LAT2-4F2hc demonstrated enhanced uptake of [(14)C]MeHg when administered as the L-cysteine or D,L-homocysteine complexes, but not when administered as the D-cysteine, N -acetyl-L-cysteine, penicillamine or GSH complexes. Penicillamine 222-235 solute carrier family 3 member 2 Homo sapiens 38-43 12237339-4 2002 Xenopus laevis oocytes expressing rat Oat1 showed increased uptake of [(14)C]MeHg when complexed with either NAC or DMPS but not when complexed with L-cysteine, glutathione, dimercaptosuccinate, penicillamine, or gamma-glutamylcysteine. Penicillamine 195-208 solute carrier family 22 member 6 Rattus norvegicus 38-42 12238917-1 2002 Replacing Cys(5) by Pen (penicillamine, beta,beta-dimethylcysteine) in the cyclic C-terminal U-II octapeptide, U-II(4-11), we have obtained a potent urotensin II (U-II) receptor agonist. Penicillamine 20-23 urotensin 2 Homo sapiens 93-97 12238917-1 2002 Replacing Cys(5) by Pen (penicillamine, beta,beta-dimethylcysteine) in the cyclic C-terminal U-II octapeptide, U-II(4-11), we have obtained a potent urotensin II (U-II) receptor agonist. Penicillamine 20-23 urotensin 2 Homo sapiens 111-115 12238917-1 2002 Replacing Cys(5) by Pen (penicillamine, beta,beta-dimethylcysteine) in the cyclic C-terminal U-II octapeptide, U-II(4-11), we have obtained a potent urotensin II (U-II) receptor agonist. Penicillamine 20-23 urotensin 2 Homo sapiens 149-161 12238917-1 2002 Replacing Cys(5) by Pen (penicillamine, beta,beta-dimethylcysteine) in the cyclic C-terminal U-II octapeptide, U-II(4-11), we have obtained a potent urotensin II (U-II) receptor agonist. Penicillamine 20-23 urotensin 2 Homo sapiens 111-115 12238917-1 2002 Replacing Cys(5) by Pen (penicillamine, beta,beta-dimethylcysteine) in the cyclic C-terminal U-II octapeptide, U-II(4-11), we have obtained a potent urotensin II (U-II) receptor agonist. Penicillamine 25-38 urotensin 2 Homo sapiens 93-97 12238917-1 2002 Replacing Cys(5) by Pen (penicillamine, beta,beta-dimethylcysteine) in the cyclic C-terminal U-II octapeptide, U-II(4-11), we have obtained a potent urotensin II (U-II) receptor agonist. Penicillamine 25-38 urotensin 2 Homo sapiens 111-115 12238917-1 2002 Replacing Cys(5) by Pen (penicillamine, beta,beta-dimethylcysteine) in the cyclic C-terminal U-II octapeptide, U-II(4-11), we have obtained a potent urotensin II (U-II) receptor agonist. Penicillamine 25-38 urotensin 2 Homo sapiens 149-161 12238917-1 2002 Replacing Cys(5) by Pen (penicillamine, beta,beta-dimethylcysteine) in the cyclic C-terminal U-II octapeptide, U-II(4-11), we have obtained a potent urotensin II (U-II) receptor agonist. Penicillamine 25-38 urotensin 2 Homo sapiens 111-115 12238917-1 2002 Replacing Cys(5) by Pen (penicillamine, beta,beta-dimethylcysteine) in the cyclic C-terminal U-II octapeptide, U-II(4-11), we have obtained a potent urotensin II (U-II) receptor agonist. Penicillamine 40-66 urotensin 2 Homo sapiens 93-97 12238917-1 2002 Replacing Cys(5) by Pen (penicillamine, beta,beta-dimethylcysteine) in the cyclic C-terminal U-II octapeptide, U-II(4-11), we have obtained a potent urotensin II (U-II) receptor agonist. Penicillamine 40-66 urotensin 2 Homo sapiens 111-115 12238917-1 2002 Replacing Cys(5) by Pen (penicillamine, beta,beta-dimethylcysteine) in the cyclic C-terminal U-II octapeptide, U-II(4-11), we have obtained a potent urotensin II (U-II) receptor agonist. Penicillamine 40-66 urotensin 2 Homo sapiens 149-161 12238917-1 2002 Replacing Cys(5) by Pen (penicillamine, beta,beta-dimethylcysteine) in the cyclic C-terminal U-II octapeptide, U-II(4-11), we have obtained a potent urotensin II (U-II) receptor agonist. Penicillamine 40-66 urotensin 2 Homo sapiens 111-115 12453634-6 2002 Copper chelator, penicillamine also inhibited the CP/H(2)O(2) system-induced alpha-synuclein aggregation. Penicillamine 17-30 synuclein alpha Homo sapiens 77-92 11721763-8 2001 A standard penicillamine treatment for 3-8.5 yr further decreased their serum ceruloplasmin levels. Penicillamine 11-24 ceruloplasmin Homo sapiens 78-91 12175101-0 2002 D-penicillamine cooperates with copper sulfate to enhance the surface expression of functional Fas antigen in rheumatoid synovial fibroblasts via the generation of hydrogen peroxide. Penicillamine 0-15 Fas cell surface death receptor Homo sapiens 95-106 12175101-2 2002 To determine whether this inhibitory action is involved in Fas-mediated apoptosis, we examined the effect of DP and copper sulfate on the expression and function of Fas antigen in rheumatoid synovial fibroblasts (RSFs). Penicillamine 109-111 Fas cell surface death receptor Homo sapiens 165-176 12175101-15 2002 CONCLUSIONS: Our data demonstrated that DP cooperated with copper sulfate to enhance the cells surface expression of functional Fas antigen in RSFs. Penicillamine 40-42 Fas cell surface death receptor Homo sapiens 128-139 11958955-6 2002 Copper chelators, diethyldithiocarbamate and penicillamine, also inhibited the Cu,Zn-SOD/H(2)O(2) system-induced alpha-synuclein aggregation. Penicillamine 45-58 superoxide dismutase 1 Homo sapiens 85-88 11958955-6 2002 Copper chelators, diethyldithiocarbamate and penicillamine, also inhibited the Cu,Zn-SOD/H(2)O(2) system-induced alpha-synuclein aggregation. Penicillamine 45-58 synuclein alpha Homo sapiens 113-128 11888918-11 2002 In the latter case, > or = 80% of the PEN-induced apoptosis was dependent on the presence of wild-type p53. Penicillamine 41-44 tumor protein p53 Homo sapiens 106-109 11841570-5 2002 Their rank order of potency in P2X4 and P2X7 receptors was carnosine = PA = His > BPh > Glycine (Gly) and carnosine = BPh = His > PA > Gly, respectively. Penicillamine 71-73 purinergic receptor P2X 4 Rattus norvegicus 31-35 11379039-10 2001 Meanwhile, lipopolysaccharide (LPS) or LPS plus interferon-gamma (IFN-gamma) induced NO production by RAW264.7 cells were suppressed by KE-758 and auranofin but not by D-penicillamine and bucillamine. Penicillamine 168-183 interferon gamma Mus musculus 48-75 10858308-3 2000 In contrast, the antiarthritis drug D-penicillamine, D-PEN, which differs from D-Cys only by the presence of two methyl groups on the beta-carbon, inhibits ZnCPD by promoting the release of the active-site zinc. Penicillamine 36-51 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 55-58 11398852-8 2001 This study demonstrates a microstructural change in the perichondrium-periosteum with decreased elastin and increased elastic microfibrils content in penicillamine treated chicks. Penicillamine 150-163 elastin Homo sapiens 96-103 11279704-4 2001 OBJECTIVES: To answer the question: Among very low birth weight infants, what is the effect of prophylactic administration of d-penicillamine on the incidence of acute ROP or severe ROP, and side effects including death? Penicillamine 126-141 opsin 1, long wave sensitive Homo sapiens 168-171 11279704-4 2001 OBJECTIVES: To answer the question: Among very low birth weight infants, what is the effect of prophylactic administration of d-penicillamine on the incidence of acute ROP or severe ROP, and side effects including death? Penicillamine 126-141 opsin 1, long wave sensitive Homo sapiens 182-185 11279704-17 2001 REVIEWER"S CONCLUSIONS: D-penicillamine is unlikely to affect survival, and may reduce the incidence of acute ROP among survivors. Penicillamine 24-39 opsin 1, long wave sensitive Homo sapiens 110-113 11113937-0 2000 High performance liquid chromatography analysis of D-penicillamine by derivatization with N-(1-pyrenyl)maleimide (NPM). Penicillamine 51-66 nucleophosmin 1 Rattus norvegicus 114-117 11082431-2 2000 The delta-opioid receptor-selective peptide D-penicillamine(2,5) (DPDPE), a Met-enkephalin analog, produces analgesia via a central nervous system-derived effect. Penicillamine 44-59 proopiomelanocortin Homo sapiens 76-90 10826917-4 2000 LADH inactivation by MPO/H2O2/NaCl and by NaOCl was similarly prevented by thiol compounds such as GSH, L-cysteine, N-acetylcysteine, penicillamine and N-(2-mercaptopropionyl-glycine) in agreement with the role of HOCI in LADH inactivation by MPO/H2O2/NaCl. Penicillamine 134-147 myeloperoxidase Sus scrofa 21-24 10852254-1 2000 OBJECTIVE: To investigate the mechanism of autoimmune phenomena, occasionally seen in patients with rheumatoid arthritis treated with bucillamine (BUC) and D-penicillamine (D-Pen), by evaluating their effects on apoptosis of T cells induced by T cell receptor activation or dexamethasone. Penicillamine 156-171 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 175-178 10555917-1 1999 A 66-year-old Japanese woman with severe scleroderma developed anemia and thrombocytopenia due to D-penicillamine (D-Pen) treatment, although the leukopenia was not markedly severe. Penicillamine 98-113 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 117-120 10940226-3 2000 We tested the copper chelators trientine, penicillamine, and bathophenanthroline for their ability to mobilize brain Abeta as measured against our benchmark compound bathocuproine (BC). Penicillamine 42-55 amyloid beta precursor protein Homo sapiens 117-122 10815633-14 2000 Penicillamine, an SH-containing compound with weak ACE inhibitory activity was also a strong antifibrotic agent but showed only modest anti-inflammatory properties. Penicillamine 0-13 angiotensin I converting enzyme Rattus norvegicus 51-54 10782806-1 2000 OBJECTIVE: To clarify the effect of bucillamine, an antirheumatic drug related to D-penicillamine, on the development of human Th1 and Th2 cells in vitro. Penicillamine 82-97 negative elongation factor complex member C/D Homo sapiens 127-130 10669180-1 2000 BACKGROUND: Oral chelation therapy with d-penicillamine (d-PCN) has been proven to be effective in the treatment of mild-to-moderate lead poisoning. Penicillamine 40-55 pericentrin Homo sapiens 59-62 10796241-2 2000 OBJECTIVES: To answer the question: Among very low birth weight infants, what is the effect of prophylactic administration of d-penicillamine on the incidence of acute ROP or severe ROP, and side effects including death? Penicillamine 126-141 opsin 1, long wave sensitive Homo sapiens 168-171 10796241-2 2000 OBJECTIVES: To answer the question: Among very low birth weight infants, what is the effect of prophylactic administration of d-penicillamine on the incidence of acute ROP or severe ROP, and side effects including death? Penicillamine 126-141 opsin 1, long wave sensitive Homo sapiens 182-185 10796241-14 2000 REVIEWER"S CONCLUSIONS: D-penicillamine is unlikely to affect survival, and may reduce the incidence of acute ROP among survivors. Penicillamine 24-39 opsin 1, long wave sensitive Homo sapiens 110-113 10938528-1 2000 The objective of this study was to evaluate the effect of a nitric oxide (NO) donor, S-nitroso-N-acetyl-DL-penicillamine (SNAP), on the nasal absorption of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rabbits and to evaluate the irritation (cytotoxicity) potential of the NO donor on the mucosal membrane using a cultured cell system (strain KB, human epidermoid carcinoma of the floor of the mouth). Penicillamine 107-120 colony stimulating factor 3 Homo sapiens 174-211 10523391-6 1999 The SH compounds NAC, penicillamine, and MPG but not the non-SH compound enalaprilat also significantly raised Mg(i) in erythrocytes (P<0.05). Penicillamine 22-35 CMS1A1 Homo sapiens 111-116 10565262-0 1999 Regulation of type I collagen and interstitial collagenase mRNA expression in human dermal fibroblasts by colchicine and D-penicillamine. Penicillamine 121-136 matrix metallopeptidase 1 Homo sapiens 34-58 10408968-0 1999 T cell responses to D-penicillamine in drug-induced myasthenia gravis: recognition of modified DR1:peptide complexes. Penicillamine 20-35 down-regulator of transcription 1 Homo sapiens 95-98 11671035-2 1999 Anti and syn refer to the relationship of the oxo ligand and carboxyl group of the cysteine/penicillamine residue. Penicillamine 92-105 synemin Homo sapiens 9-12 10366112-1 1999 OBJECTIVE: To test the hypothesis that systemic sclerosis (SSc) patients taking high-dose D-penicillamine (D-Pen) would have greater softening of skin, lower frequency of renal crisis, and better survival than patients taking low-dose D-Pen. Penicillamine 90-105 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 109-112 10366112-1 1999 OBJECTIVE: To test the hypothesis that systemic sclerosis (SSc) patients taking high-dose D-penicillamine (D-Pen) would have greater softening of skin, lower frequency of renal crisis, and better survival than patients taking low-dose D-Pen. Penicillamine 90-105 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 237-240 10408968-1 1999 The anti-rheumatoid drug D-penicillamine (D-pen) has a reactive sulfhydryl group capable of modifying self antigens, and can provoke typical autoantibody-mediated myasthenia gravis (MG), especially in DR1+ individuals. Penicillamine 25-40 down-regulator of transcription 1 Homo sapiens 201-204 10408968-1 1999 The anti-rheumatoid drug D-penicillamine (D-pen) has a reactive sulfhydryl group capable of modifying self antigens, and can provoke typical autoantibody-mediated myasthenia gravis (MG), especially in DR1+ individuals. Penicillamine 25-30 down-regulator of transcription 1 Homo sapiens 201-204 10408968-5 1999 Thus, D-pen may directly couple to distinctive peptides resident in surface DR1 molecules on circulating macrophages or dendritic cells. Penicillamine 6-11 down-regulator of transcription 1 Homo sapiens 76-79 10381063-2 1999 We describe 3 patients with accelerated nodulosis treated with D-penicillamine (D-Pen) while continuing MTX. Penicillamine 63-78 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 82-85 9837698-1 1998 D-penicillamine (d-PA) was reported to induce various immunological abnormalities including production of autoantibodies to insulin. Penicillamine 0-15 insulin Homo sapiens 124-131 10193578-8 1999 L-cysteine, N-acetylcysteine, penicillamine, N-(2-mercaptopropionylglycine), Captopril and taurine protected LADH against MPO systems and NaOCl. Penicillamine 30-43 myeloperoxidase Equus caballus 122-125 9989295-10 1999 Development of extracapillary glomerulonephritis with anti-MPO in patients who are taking D-penicillamine suggests that inductor mechanisms other than D-penicillamine are involved in the pathogenesis of these glomerulopathies. Penicillamine 90-105 myeloperoxidase Homo sapiens 59-62 9989295-10 1999 Development of extracapillary glomerulonephritis with anti-MPO in patients who are taking D-penicillamine suggests that inductor mechanisms other than D-penicillamine are involved in the pathogenesis of these glomerulopathies. Penicillamine 151-166 myeloperoxidase Homo sapiens 59-62 9837698-1 1998 D-penicillamine (d-PA) was reported to induce various immunological abnormalities including production of autoantibodies to insulin. Penicillamine 17-21 insulin Homo sapiens 124-131 9727867-2 1998 In this study penicillamine (Pen) was substituted for one or both of the cysteinyl residues to determine conformational and topographical properties of the disulphide bridge favourable for binding to CGRP receptors and/or receptor activation. Penicillamine 14-27 Calcitonin gene-related peptide Sus scrofa 200-204 9727867-2 1998 In this study penicillamine (Pen) was substituted for one or both of the cysteinyl residues to determine conformational and topographical properties of the disulphide bridge favourable for binding to CGRP receptors and/or receptor activation. Penicillamine 29-32 Calcitonin gene-related peptide Sus scrofa 200-204 9674417-0 1998 D-penicillamine-induced pemphigus foliaceus with autoantibodies to desmoglein-1. Penicillamine 0-15 desmoglein 1 Homo sapiens 67-79 9581011-9 1998 Another drug, penicillamine, that protects cellular membranes against toxic oxygen in vitro, is presumed to act as an antirheumatic via the SOD mimetic activity of its copper complex. Penicillamine 14-27 superoxide dismutase 1 Homo sapiens 140-143 9354586-8 1997 A third group, which consisted of levodopa, D-penicillamine, and muzolimine, inhibited PLK using PL, but not PM, as substrate. Penicillamine 44-59 pyridoxal kinase Homo sapiens 87-90 9267106-2 1997 A 20-year-old man with hepatolenticular degeneration, under prolonged treatment with D-penicillamine, presented with a circular or serpiginous arrangement of nuchal papules. Penicillamine 85-100 immunoglobulin kappa variable 1-27 Homo sapiens 0-4 9323023-4 1997 At low thiol:ONOO- concentration ratios, several thiols (captopril, penicillamine, cysteine, cystine and penicillamine disulphide) aggravated inactivation of alpha1AP by ONOO- , whereas GSH, GSSG, homocysteine, ergothioneine, N-acetylcysteine, lipoate and dihydrolipoate did not. Penicillamine 68-81 serpin family A member 1 Homo sapiens 158-166 9240414-4 1997 To test this hypothesis in vivo, we administered the copper chelator d-penicillamine to a transgenic mouse model of familial amyotrophic lateral sclerosis overexpressing a mutated form of human SOD1. Penicillamine 69-84 superoxide dismutase 1 Homo sapiens 194-198 9216536-0 1997 D-penicillamine-induced pemphigus foliaceus with autoantibodies to desmoglein-1 in a patient with mixed connective tissue disease. Penicillamine 0-15 desmoglein 1 Homo sapiens 67-79 9182889-0 1997 Gold and D-penicillamine induce vasculitis and up-regulate mRNA for IL-4 in the Brown Norway rat: support for a role for Th2 cell activity. Penicillamine 9-24 interleukin 4 Rattus norvegicus 68-72 9182889-4 1997 DP, gold salts and mercuric chloride (HgCl2) are known to induce Th2-dominated autoimmune syndromes in genetically susceptible rodent strains, and we have demonstrated recently that HgCl2 up-regulates messenger RNA (mRNA) for IL-4 in the Brown Norway (BN) rat. Penicillamine 0-2 interleukin 4 Rattus norvegicus 226-230 9002016-7 1997 In one patient, anti-MPO antibodies appeared in the serum only after D-penicillamine was introduced, continued to rise after withdrawal of the drug, and fell only after immunosuppressive therapy. Penicillamine 69-84 myeloperoxidase Homo sapiens 21-24 9377846-3 1997 The authors describe the drugs employed in the therapy of the PBC: cortisone, azathioprine, metotrexate, chlorambucil, colchicine, D-penicillamine and hydrophilic bile salts; the favourable risk-benefice rate of colchicine, azathioprine and hydrophilic bile salts is outlined, even if they are poorly active on the disease"s course. Penicillamine 131-146 dihydrolipoamide S-acetyltransferase Homo sapiens 62-65 9076692-4 1997 It is reasonable to consider that the cysteine-penicillamine disulfide is continuing to be enzymatically reduced by various thiol reductants, in particular glutathione reductase, thereby generating a "new" penicillamine molecule which, in turn, reacts with other cystine disulfides and does so in an unending cycle. Penicillamine 47-60 glutathione-disulfide reductase Homo sapiens 156-177 8794887-0 1996 D-penicillamine causes free radical-dependent inactivation of activator protein-1 DNA binding. Penicillamine 0-15 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 62-81 8794887-4 1996 The current study demonstrates that AP-1 DNA binding is inhibited by D-penicillamine in the presence of Fenton reagents (Fe2+/EDTA and H2O2) but not with either agent alone. Penicillamine 69-84 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 36-40 8794887-8 1996 Mutant proteins were used to identify the cysteine residues within the DNA binding domains of Jun and Fos that are essential for the inhibitory action of D-penicillamine. Penicillamine 154-169 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 102-105 8794887-9 1996 The results suggest that D-penicillamine is distinguished from other thiols by its formation of sulfur-containing radicals capable of inhibiting AP-1 DNA binding by a mechanism involving the cysteine residues of Jun and Fos. Penicillamine 25-40 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 145-149 8794887-9 1996 The results suggest that D-penicillamine is distinguished from other thiols by its formation of sulfur-containing radicals capable of inhibiting AP-1 DNA binding by a mechanism involving the cysteine residues of Jun and Fos. Penicillamine 25-40 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 220-223 8834013-3 1996 Corticosteroids inhibit the transcription of a broad spectrum of genes including those encoding monocyte, T cell-derived cytokines and several hemopoietic growth factors, whereas drugs such as cyclosporin A and D-penicillamine interfere with T cell activation more specifically by suppressing interleukin 2 (IL-2) production. Penicillamine 211-226 interleukin 2 Homo sapiens 293-306 8834013-3 1996 Corticosteroids inhibit the transcription of a broad spectrum of genes including those encoding monocyte, T cell-derived cytokines and several hemopoietic growth factors, whereas drugs such as cyclosporin A and D-penicillamine interfere with T cell activation more specifically by suppressing interleukin 2 (IL-2) production. Penicillamine 211-226 interleukin 2 Homo sapiens 308-312 8547339-8 1996 When the bacterial cells were treated with D-penicillamine, a copper chelator, formation of the active CPO was partially reduced. Penicillamine 43-58 coproporphyrinogen oxidase Mus musculus 103-106 8592607-0 1995 Goodpasture-like syndrome associated with anti-myeloperoxidase antibodies following penicillamine treatment. Penicillamine 84-97 myeloperoxidase Homo sapiens 47-62 8788233-1 1995 The in vitro activity of gelatinase B, an enzyme whose appearance in the cerebrospinal fluid is associated with inflammatory diseases of the central nervous system, was dose-dependently inhibited by the antirheumatic D-penicillamine. Penicillamine 217-232 matrix metallopeptidase 9 Mus musculus 25-37 8788233-2 1995 Inhibition of gelatinase B in electrophoretically pure preparations and in cell culture supernatants and human body fluids was obtained at dosages reached in the circulation of patients treated with a peroral dosis of 750 mg D-penicillamine per day. Penicillamine 225-240 matrix metallopeptidase 9 Mus musculus 14-26 7757200-8 1995 100 microM GSH, DL-dithiothreitol, N-(2-mercaptopropionylglicine) and penicillamine protected LADH against Cu(II)/Asc and Cu(II), whereas 1.0 mm GSH and DL-dithiothreitol also protected LADH against Cu(II)/H2O2. Penicillamine 70-83 dihydrolipoamide dehydrogenase Sus scrofa 94-98 7586781-1 1995 OBJECTIVE: We have previously shown that the administration of D-penicillamine (D-PEN) to patients with rheumatoid arthritis induces circulating insulin autoantibodies (INSAAB). Penicillamine 63-78 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 82-85 7586781-1 1995 OBJECTIVE: We have previously shown that the administration of D-penicillamine (D-PEN) to patients with rheumatoid arthritis induces circulating insulin autoantibodies (INSAAB). Penicillamine 63-78 insulin Homo sapiens 145-152 7757200-8 1995 100 microM GSH, DL-dithiothreitol, N-(2-mercaptopropionylglicine) and penicillamine protected LADH against Cu(II)/Asc and Cu(II), whereas 1.0 mm GSH and DL-dithiothreitol also protected LADH against Cu(II)/H2O2. Penicillamine 70-83 dihydrolipoamide dehydrogenase Sus scrofa 186-190 7649526-11 1995 Under a combined therapy with D-penicillamine and GH, serum liver enzymes decreased, and IGF-I levels increased to normal. Penicillamine 30-45 insulin like growth factor 1 Homo sapiens 89-94 7836960-0 1994 Dopamine D2 receptor binding and cerebral glucose metabolism recover after D-penicillamine-therapy in Wilson"s disease. Penicillamine 75-90 dopamine receptor D2 Homo sapiens 0-20 8082232-2 1994 It was found that L-cysteine, L-cysteine methyl ester and D-penicillamine were very efficient reductants for cytochrome c, whereas N-acetylated amino acids (N-acetyl-L-cysteine and N-acetyl-D-cysteine) reacted considerably slower. Penicillamine 58-73 cytochrome c, somatic Homo sapiens 109-121 7799341-1 1994 OBJECTIVE: To determine whether intermittent rather than daily administration of D-penicillamine (D-Pen) would effectively reduce the incidence of adverse effects without significantly diminishing the clinical benefits. Penicillamine 81-96 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 100-103 7953197-0 1994 Effects of cyclosporin-A and D-penicillamine on the development of hepatitis and the production of antibody to protein disulfide isomerase in LEC rats. Penicillamine 29-44 prolyl 4-hydroxylase subunit beta Rattus norvegicus 111-138 8003068-7 1994 DP (3 micrograms/ml) significantly suppressed IFN gamma production by immobilized anti-CD3-stimulated CD4+ T cells, but not IgM production induced by SAC + IL-2 stimulation. Penicillamine 0-2 interferon gamma Homo sapiens 46-55 7932438-2 1994 B19 induced aplastic crises were the revealing manifestations of asymptomatic hemolytic conditions in the 2 patients: a Coombs" positive hemolytic anemia induced by D-penicillamine in the first and congenital spherocytosis in the second. Penicillamine 165-180 eva-1 homolog C Homo sapiens 0-3 8208404-0 1994 Treatment with D-penicillamine improves dopamine D2-receptor binding and T2-signal intensity in de novo Wilson"s disease. Penicillamine 15-30 dopamine receptor D2 Homo sapiens 40-60 8208404-1 1994 We report the results of in vivo striatal dopamine D2-receptor binding assessed by PET using 11C-raclopride (only one patient) and by single-photon emission computed tomography (SPECT) using 123I-iodobenzamide (123I-IBZM) and the findings of T2-weighted MRIs in two de novo Wilson"s disease patients before and 4 months after initiation of D-penicillamine treatment. Penicillamine 340-355 dopamine receptor D2 Homo sapiens 42-62 8152263-7 1994 Acetaminophen, N-acetylcysteine, propylthiouracil, D-penicillamine, mefenamic acid, dapsone, and methimazole all inhibited MPO at clinically achievable concentrations. Penicillamine 51-66 myeloperoxidase Homo sapiens 123-126 8221705-3 1993 Because of relatively low levels of serum copper and ceruloplasmin, D-penicillamine was administered. Penicillamine 68-83 ceruloplasmin Homo sapiens 53-66 8156144-10 1993 In caucasoids DR4 was increased in D-penicillamine induced IMD but again there may be inter-racial differences. Penicillamine 35-50 major histocompatibility complex, class II, DR beta 4 Homo sapiens 14-17 8409755-0 1993 Antirheumatic gold compounds and penicillamine enhance protein kinase C-mediated activation of the arachidonate-mobilizing phospholipase A2 in mouse macrophages. Penicillamine 33-46 phospholipase A2, group IB, pancreas Mus musculus 123-139 8282535-2 1993 When incubating human peripheral blood lymphocytes with D-penicillamine or bucillamine in the presence of 8 microM CuSO4, numerous DNA strand breaks occurred and those depended on the production of hydrogen peroxide and were completely blocked in the presence of catalase. Penicillamine 56-71 catalase Homo sapiens 263-271 18965799-2 1993 The chemical equilibria involved in nine mixed ligand systems Zn(II)-L-cysteine (Cys)/D-penicillamine(Pen)/L-cysteic acid(Cya)(A)-imidazole(Him), histamine(Hist) and L-histidine(His)(B) have been investigated in aqueous perchlorate medium by pH titrimetry at 37 degrees and ionic strength, I = 0.15M (NaClO(4)). Penicillamine 86-101 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 102-105 7685225-4 1993 The DMARDs such as gold salts, D-penicillamine, sulphasalazine and azathioprine have been shown to reduce serum CRP concentrations significantly in patients with RA. Penicillamine 31-46 C-reactive protein Homo sapiens 112-115 8318649-4 1993 However, in the presence of glutathione, cysteine, penicillamine, or N-acetylcysteine, Co(II) generated cumene-OOH-derived carbon-centered radicals, cumene alkoxyl radicals, and hydroxyl (.OH) radicals. Penicillamine 51-64 mitochondrially encoded cytochrome c oxidase II Homo sapiens 87-93 8485889-0 1993 Interferences of bilirubin, ascorbic acid, dipyrone, and D-penicillamine in two assays of 5"-nucleotidase. Penicillamine 57-72 5'-nucleotidase ecto Homo sapiens 90-105 8428039-6 1993 The results have shown progressively decreasing amounts of PAI-1 in penicillamine, thiopronine and captopril-cultured tissue extracts, respectively. Penicillamine 68-81 serpin family E member 1 Homo sapiens 59-64 8442754-1 1993 Effects of methylene blue, cyanamide and penicillamine on the redox state of the bound coenzyme and on the substrate exchange at alcohol dehydrogenase. Penicillamine 41-54 aldo-keto reductase family 1 member A1 Rattus norvegicus 129-150 1288876-4 1992 Haem synthesis inhibitors (succinylacetone, isonicotinic acid hydrazide and penicillamine) caused a reduced gene expression for ferrochelatase in erythroleukaemic cells of mice induced with hexamethylenebisacetamide. Penicillamine 76-89 ferrochelatase Mus musculus 128-142 1464863-0 1992 Frequent induction of insulin autoantibodies by D-penicillamine in patients with rheumatoid arthritis. Penicillamine 48-63 insulin Homo sapiens 22-29 1466536-5 1992 Penicillamine is known to alter cross-linking of elastin and collagen fibers. Penicillamine 0-13 elastin Homo sapiens 49-56 1464863-4 1992 Nine of these 11 (81.8%) insulin autoantibodies positive patients had been treated with D-penicillamine. Penicillamine 88-103 insulin Homo sapiens 25-32 1464863-5 1992 Out of 21 D-penicillamine treated patients, 9 (42.9%) were insulin autoantibodies positive (range 80 to 1970 nU/ml). Penicillamine 10-25 insulin Homo sapiens 59-66 1464863-8 1992 In summary, elevated concentration of serum insulin autoantibodies are most probably induced by D-penicillamine therapy in patients with RA and tend to decrease after the drug withdrawal. Penicillamine 96-111 insulin Homo sapiens 44-51 1358240-3 1992 The drugs sodium aurothiomalate, D-penicillamine and sulphasalazine were all able to modulate IL-8 mRNA synthesis in and protein secretion from endothelial cells. Penicillamine 33-48 C-X-C motif chemokine ligand 8 Homo sapiens 94-98 1569181-2 1992 Incubation of FVIII-EH plasma with penicillamine or DTT causes a five- to sixfold increase in FVIII-EH VIII:C, at 80 and 1 mM, respectively. Penicillamine 35-48 coagulation factor VIII Homo sapiens 14-19 1622412-7 1992 Furthermore, Ro/SS-A antibodies were associated with a high incidence of side effects to D-penicillamine only in the Greeks. Penicillamine 89-104 tripartite motif containing 21 Homo sapiens 13-20 1597863-3 1992 Spin echo NMR analysis is used to monitor the effect of penicillamine on intact erythrocytes obtained from patients suffering from rheumatoid arthritis during a 12-week period of therapy. Penicillamine 56-69 spindlin 1 Homo sapiens 0-4 1597863-12 1992 This initial study suggests that spin-echo NMR analysis of erythrocyte glutathione can act as an early indicator of a clinical response to penicillamine therapy. Penicillamine 139-152 spindlin 1 Homo sapiens 33-37 1458162-1 1992 The mechanism of the antioxidative effect of D-penicillamine was studied under the conditions of NADPH- and CCl4-dependent lipid peroxidation in microsomes of rat liver and adrenalin autooxidation reaction. Penicillamine 45-60 C-C motif chemokine ligand 4 Rattus norvegicus 108-112 1569181-2 1992 Incubation of FVIII-EH plasma with penicillamine or DTT causes a five- to sixfold increase in FVIII-EH VIII:C, at 80 and 1 mM, respectively. Penicillamine 35-48 coagulation factor VIII Homo sapiens 94-99 1569181-2 1992 Incubation of FVIII-EH plasma with penicillamine or DTT causes a five- to sixfold increase in FVIII-EH VIII:C, at 80 and 1 mM, respectively. Penicillamine 35-48 cytochrome c oxidase subunit 8A Homo sapiens 15-19 1569181-3 1992 While there is no FVIII-EH light chain cleavage when thrombin is added in the presence of penicillamine or DTT, these reducing agents disrupt the FVIII-vWf complex. Penicillamine 90-103 coagulation factor II, thrombin Homo sapiens 53-61 1564250-1 1992 D-Penicillamine (DPA) causes axial skeletal defects in rats and fetal lethality when given as 0.83% and 1.6% of the diet, but its mechanism of action on the axial skeleton is unknown. Penicillamine 0-15 D-phenylalanine Mus musculus 17-20 1863202-0 1991 Synergistic inhibition of aminopeptidase B by penicillamine or cysteine and metallic salts. Penicillamine 46-59 arginyl aminopeptidase Homo sapiens 26-42 1570481-1 1992 Nine cases of penicillamine induced pemphigus (PIP) in rheumatoid arthritis patients are reported. Penicillamine 14-27 prolactin induced protein Homo sapiens 47-50 1765973-4 1991 Increased serum levels of alpha 1-antitrypsin were independently associated (p less than 0.01) with the presence of wrist joint erosions and the use of gold and/or penicillamine for treatment; this association may represent a serum antitrypsin response to more severe disease. Penicillamine 164-177 serpin family A member 1 Homo sapiens 26-45 1776370-0 1991 D-penicillamine-induced agranulocytosis: hematological remission upon treatment with recombinant GM-CSF. Penicillamine 0-15 colony stimulating factor 2 Homo sapiens 97-103 1712069-0 1991 Covalent disulfide binding of human IL-1 beta to alpha 2-macroglobulin: inhibition by D-penicillamine. Penicillamine 86-101 interleukin 1 beta Homo sapiens 36-45 1709917-3 1991 Binding of PA and BP to rat peritoneal exudate cells was detected by a cell ELISA, employing rabbit antisera specific for each drug, and an indicator system employing a second antibody coupled to biotin-streptavidin-beta-galactosidase. Penicillamine 11-13 galactosidase, beta 1 Rattus norvegicus 216-234 1712069-0 1991 Covalent disulfide binding of human IL-1 beta to alpha 2-macroglobulin: inhibition by D-penicillamine. Penicillamine 86-101 alpha-2-macroglobulin Homo sapiens 49-70 1712069-9 1991 The addition of D-penicillamine (D-pen) during the reaction of [125I]rIL-1 beta with serum or purified alpha 2M blocked the covalent binding of rIL-1 beta to alpha 2M. Penicillamine 16-31 interleukin 1 beta Rattus norvegicus 69-79 1712069-9 1991 The addition of D-penicillamine (D-pen) during the reaction of [125I]rIL-1 beta with serum or purified alpha 2M blocked the covalent binding of rIL-1 beta to alpha 2M. Penicillamine 16-31 alpha-2-macroglobulin Homo sapiens 103-111 1712069-9 1991 The addition of D-penicillamine (D-pen) during the reaction of [125I]rIL-1 beta with serum or purified alpha 2M blocked the covalent binding of rIL-1 beta to alpha 2M. Penicillamine 16-31 interleukin 1 beta Rattus norvegicus 144-154 1712069-9 1991 The addition of D-penicillamine (D-pen) during the reaction of [125I]rIL-1 beta with serum or purified alpha 2M blocked the covalent binding of rIL-1 beta to alpha 2M. Penicillamine 16-31 alpha-2-macroglobulin Homo sapiens 158-166 1712069-9 1991 The addition of D-penicillamine (D-pen) during the reaction of [125I]rIL-1 beta with serum or purified alpha 2M blocked the covalent binding of rIL-1 beta to alpha 2M. Penicillamine 16-21 interleukin 1 beta Rattus norvegicus 69-79 1712069-9 1991 The addition of D-penicillamine (D-pen) during the reaction of [125I]rIL-1 beta with serum or purified alpha 2M blocked the covalent binding of rIL-1 beta to alpha 2M. Penicillamine 16-21 alpha-2-macroglobulin Homo sapiens 103-111 1712069-9 1991 The addition of D-penicillamine (D-pen) during the reaction of [125I]rIL-1 beta with serum or purified alpha 2M blocked the covalent binding of rIL-1 beta to alpha 2M. Penicillamine 16-21 interleukin 1 beta Rattus norvegicus 144-154 1712069-9 1991 The addition of D-penicillamine (D-pen) during the reaction of [125I]rIL-1 beta with serum or purified alpha 2M blocked the covalent binding of rIL-1 beta to alpha 2M. Penicillamine 16-21 alpha-2-macroglobulin Homo sapiens 158-166 1712069-14 1991 rIL-1 beta attached to alpha 2M in the presence or absence of D-pen showed similar biological activity in the mouse thymocyte-assay. Penicillamine 62-67 interleukin 1 beta Rattus norvegicus 0-10 1712069-17 1991 We concluded that human rIL-1 beta binds to alpha 2M through the Cys at position 8 and that D-pen inhibits this binding. Penicillamine 92-97 interleukin 1 beta Rattus norvegicus 24-34 1712069-17 1991 We concluded that human rIL-1 beta binds to alpha 2M through the Cys at position 8 and that D-pen inhibits this binding. Penicillamine 92-97 alpha-2-macroglobulin Homo sapiens 44-52 1677490-4 1991 Eleven of 16 with MGN had been treated with gold, bucillamine or D-penicillamine, so they were diagnosed as drug induced MGN. Penicillamine 65-80 helt bHLH transcription factor Homo sapiens 18-21 1676628-1 1991 D-penicillamine (D-PEN) is incompletely recovered during short-term balance studies, despite rapid elimination of D-PEN and its low molecular weight metabolites. Penicillamine 0-15 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 19-22 1651290-1 1991 The previously described cyclic, delta opioid receptor-selective tetrapeptide H-Tyr-D-Cys-Phe-D-Pen-OH, where Pen, penicillamine, is beta-beta-dimethylcysteine, was modified at residues 2 and 4 by varying combinations of D- and L-Cys and D- and L-Pen, and effects on mu and delta opioid receptor binding affinities and on potency in the mouse vas deferens (MVD) smooth muscle assay were evaluated. Penicillamine 115-128 proprotein convertase subtilisin/kexin type 1 inhibitor Mus musculus 96-99 1651290-1 1991 The previously described cyclic, delta opioid receptor-selective tetrapeptide H-Tyr-D-Cys-Phe-D-Pen-OH, where Pen, penicillamine, is beta-beta-dimethylcysteine, was modified at residues 2 and 4 by varying combinations of D- and L-Cys and D- and L-Pen, and effects on mu and delta opioid receptor binding affinities and on potency in the mouse vas deferens (MVD) smooth muscle assay were evaluated. Penicillamine 115-128 proprotein convertase subtilisin/kexin type 1 inhibitor Mus musculus 110-113 1651290-1 1991 The previously described cyclic, delta opioid receptor-selective tetrapeptide H-Tyr-D-Cys-Phe-D-Pen-OH, where Pen, penicillamine, is beta-beta-dimethylcysteine, was modified at residues 2 and 4 by varying combinations of D- and L-Cys and D- and L-Pen, and effects on mu and delta opioid receptor binding affinities and on potency in the mouse vas deferens (MVD) smooth muscle assay were evaluated. Penicillamine 115-128 proprotein convertase subtilisin/kexin type 1 inhibitor Mus musculus 110-113 1651290-1 1991 The previously described cyclic, delta opioid receptor-selective tetrapeptide H-Tyr-D-Cys-Phe-D-Pen-OH, where Pen, penicillamine, is beta-beta-dimethylcysteine, was modified at residues 2 and 4 by varying combinations of D- and L-Cys and D- and L-Pen, and effects on mu and delta opioid receptor binding affinities and on potency in the mouse vas deferens (MVD) smooth muscle assay were evaluated. Penicillamine 133-159 proprotein convertase subtilisin/kexin type 1 inhibitor Mus musculus 96-99 1651290-1 1991 The previously described cyclic, delta opioid receptor-selective tetrapeptide H-Tyr-D-Cys-Phe-D-Pen-OH, where Pen, penicillamine, is beta-beta-dimethylcysteine, was modified at residues 2 and 4 by varying combinations of D- and L-Cys and D- and L-Pen, and effects on mu and delta opioid receptor binding affinities and on potency in the mouse vas deferens (MVD) smooth muscle assay were evaluated. Penicillamine 133-159 proprotein convertase subtilisin/kexin type 1 inhibitor Mus musculus 110-113 1651290-1 1991 The previously described cyclic, delta opioid receptor-selective tetrapeptide H-Tyr-D-Cys-Phe-D-Pen-OH, where Pen, penicillamine, is beta-beta-dimethylcysteine, was modified at residues 2 and 4 by varying combinations of D- and L-Cys and D- and L-Pen, and effects on mu and delta opioid receptor binding affinities and on potency in the mouse vas deferens (MVD) smooth muscle assay were evaluated. Penicillamine 133-159 proprotein convertase subtilisin/kexin type 1 inhibitor Mus musculus 110-113 1677490-4 1991 Eleven of 16 with MGN had been treated with gold, bucillamine or D-penicillamine, so they were diagnosed as drug induced MGN. Penicillamine 65-80 helt bHLH transcription factor Homo sapiens 121-124 1783039-0 1991 The effect of D-penicillamine on CCl4-induced experimental liver cirrhosis. Penicillamine 14-29 C-C motif chemokine ligand 4 Rattus norvegicus 33-37 1664200-7 1991 Treatment with D-PEN, DMSA, DMPS, and bucillamine (1.2 mmol/kg) significantly prevented increases in the urinary excretion of protein, AST, and glucose and the BUN level after AuTM (0.026 mmol/kg) injection. Penicillamine 15-20 glutamic-oxaloacetic transaminase 2 Rattus norvegicus 135-138 1783039-1 1991 The effect of D-penicillamine (Pe) on liver fibrosis-cirrhosis induced by chronic CCl4 and phenobarbital (Pb) administration in Fischer 344 male rats was studied. Penicillamine 31-33 C-C motif chemokine ligand 4 Rattus norvegicus 82-86 2222540-2 1990 D-penicillamine-induced antinuclear antibodies were mainly high-titer IgG directed against the (H2A-H2B)-DNA complex. Penicillamine 0-15 H2B clustered histone 21 Homo sapiens 100-103 1827158-0 1991 D-penicillamine toxicity in Greek patients with rheumatoid arthritis: anti-Ro(SSA) antibodies and cryoglobulinemia are predictive factors. Penicillamine 0-15 tripartite motif containing 21 Homo sapiens 78-81 1827158-3 1991 The clinical picture in both groups was similar, but the group with D-penicillamine toxicity was characterized by a high incidence of anti-Ro(SSA) antibodies (p less than 0.01) or circulating cryoglobulins (p less than 0.001). Penicillamine 68-83 tripartite motif containing 21 Homo sapiens 142-145 1977004-2 1990 Oral penicillamine therapy led to a decrease in auditory brainstem (ABP) and somatosensory (SEP) conduction times in 6 and 4 neurologically symptomatic patients, respectively. Penicillamine 5-18 amine oxidase copper containing 1 Homo sapiens 68-71 1977004-2 1990 Oral penicillamine therapy led to a decrease in auditory brainstem (ABP) and somatosensory (SEP) conduction times in 6 and 4 neurologically symptomatic patients, respectively. Penicillamine 5-18 plexin B1 Homo sapiens 92-95 1981242-7 1990 D-penicillamine inhibited IL-1 activity and tended to inhibit IL-1 production. Penicillamine 0-15 interleukin 1 alpha Homo sapiens 26-30 2291865-2 1990 The plasma pharmacokinetics of D-penicillamine (D-pen) and D-penicillamine-albumin disulphide (D-pen-alb) were examined over a dosage interval in six patients with rheumatoid arthritis. Penicillamine 59-74 albumin Homo sapiens 75-78 2291865-12 1990 The presence of D-pen-alb in relatively high concentrations throughout the dosage interval contrasts with the low concentrations and rapid elimination of D-pen. Penicillamine 16-21 albumin Homo sapiens 22-25 2225561-7 1990 The observations presented in this report indicate that 2-MPG, like D-penicillamine, could induce autoimmune reactions, in some cases leading to membranous glomerulonephritis. Penicillamine 68-83 N-methylpurine DNA glycosylase Homo sapiens 58-61 1981242-7 1990 D-penicillamine inhibited IL-1 activity and tended to inhibit IL-1 production. Penicillamine 0-15 interleukin 1 alpha Homo sapiens 62-66 2233769-0 1990 [The effect of D-penicillamine on experimental liver cirrhosis induced by CCl4]. Penicillamine 15-30 C-C motif chemokine ligand 4 Rattus norvegicus 74-78 2324766-3 1990 We report, in GAN fibroblasts, inhibition of vimentin filament aggregation by dithiothreitol and penicillamine, sulfhydryl donor compounds which stabilize thiols. Penicillamine 97-110 gigaxonin Homo sapiens 14-17 2163628-0 1990 Reaction of autoxidation products of penicillamine with myeloperoxidase. Penicillamine 37-50 myeloperoxidase Homo sapiens 56-71 2163628-1 1990 Spectral evidence is presented which shows that penicillamine is able to initiate the formation of the oxidized intermediates of myeloperoxidase in the absence of exogenous hydrogen peroxide. Penicillamine 48-61 myeloperoxidase Homo sapiens 129-144 2163628-4 1990 We also report that penicillamine can directly reduce cytochrome c and therefore, it could possibly act as a one-electron donor to myeloperoxidase. Penicillamine 20-33 cytochrome c, somatic Homo sapiens 54-66 2163628-4 1990 We also report that penicillamine can directly reduce cytochrome c and therefore, it could possibly act as a one-electron donor to myeloperoxidase. Penicillamine 20-33 myeloperoxidase Homo sapiens 131-146 2359068-1 1990 Captopril, which is a thiol containing angiotensin converting enzyme (ACE) inhibitor that has a close structural similarity to D-penicillamine, behaves as a disease modifying antirheumatic drug (DMARD) in rheumatoid arthritis (RA). Penicillamine 127-142 angiotensin I converting enzyme Homo sapiens 39-68 2359068-1 1990 Captopril, which is a thiol containing angiotensin converting enzyme (ACE) inhibitor that has a close structural similarity to D-penicillamine, behaves as a disease modifying antirheumatic drug (DMARD) in rheumatoid arthritis (RA). Penicillamine 127-142 angiotensin I converting enzyme Homo sapiens 70-73 2157034-6 1990 The non-steroidal anti-inflammatory drugs, phenylbutazone, salicylic acid, aspirin, sodium salicylate in addition to D-penicillamine and dimethylsulfoxide caused dose-dependent inhibition of the cytochrome-c reduction when the cells were stimulated by PMA. Penicillamine 117-132 cytochrome c, somatic Equus caballus 195-207 2324766-3 1990 We report, in GAN fibroblasts, inhibition of vimentin filament aggregation by dithiothreitol and penicillamine, sulfhydryl donor compounds which stabilize thiols. Penicillamine 97-110 vimentin Homo sapiens 45-53 2324766-4 1990 In addition, we describe clinical improvement in a GAN patient treated with penicillamine, despite earlier progressive disease. Penicillamine 76-89 gigaxonin Homo sapiens 51-54 10334681-0 1999 The therapeutic response to D-penicillamine in rheumatoid arthritis: influence of glutathione S-transferase polymorphisms. Penicillamine 28-43 glutathione S-transferase kappa 1 Homo sapiens 82-107 2112569-0 1990 In vitro effects of two gold compounds, and D-penicillamine on the production of interferon gamma. Penicillamine 44-59 interferon gamma Homo sapiens 81-97 2112569-2 1990 Since many patients previously studied were on Gold Sodium Thiomalate (GST), Auranofin (Auf), or D-Penicillamine (D-Pen) we have investigated the effects of these drugs on IFN gamma production using PBMC from normal controls (NC), and RA patients off GST, Auf, and D-Pen. Penicillamine 97-112 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 116-119 2281661-1 1990 In 25 patients with rheumatoid arthritis the action of D-penicilamine (Cuprenyl) on the following indices was studied: IgG, IgA, IgM, circulating immune complexes (CIC), rheumatoid factor titer (RF), T- and B-lymphocytes in the peripheral blood. Penicillamine 55-69 methyl-CpG binding domain protein 1 Homo sapiens 170-208 10334681-1 1999 OBJECTIVES: To investigate whether the therapeutic response of rheumatoid arthritis (RA) patients to D-penicillamine is associated with polymorphisms in genes of the glutathione S-transferase (GST) supergene family. Penicillamine 101-116 glutathione S-transferase kappa 1 Homo sapiens 166-191 10334681-1 1999 OBJECTIVES: To investigate whether the therapeutic response of rheumatoid arthritis (RA) patients to D-penicillamine is associated with polymorphisms in genes of the glutathione S-transferase (GST) supergene family. Penicillamine 101-116 glutathione S-transferase kappa 1 Homo sapiens 193-196 10334681-3 1999 GST typing was performed using a polymerase chain reaction-based approach and a logistic regression model was used to investigate any possible association between the therapeutic response to D-penicillamine and the GST genotype. Penicillamine 191-206 glutathione S-transferase kappa 1 Homo sapiens 215-218 10334681-5 1999 CONCLUSIONS: Our results suggest that GST polymorphisms may influence the response to D-penicillamine in RA, and that patients in possession of the GSTM1*0/GSTM3*A haplotype are significantly less likely to show a beneficial response to the drug. Penicillamine 86-101 glutathione S-transferase kappa 1 Homo sapiens 38-41 10334681-5 1999 CONCLUSIONS: Our results suggest that GST polymorphisms may influence the response to D-penicillamine in RA, and that patients in possession of the GSTM1*0/GSTM3*A haplotype are significantly less likely to show a beneficial response to the drug. Penicillamine 86-101 glutathione S-transferase mu 1 Homo sapiens 148-153 10334681-5 1999 CONCLUSIONS: Our results suggest that GST polymorphisms may influence the response to D-penicillamine in RA, and that patients in possession of the GSTM1*0/GSTM3*A haplotype are significantly less likely to show a beneficial response to the drug. Penicillamine 86-101 glutathione S-transferase mu 3 Homo sapiens 156-161 34625257-7 2021 We found that non-covalent complexes (Pen+beta-CD + Li)+ could be easily formed by electrospray ionization of the mixture of the solution, and the chirality of Pen could be effectively recognized by measuring their mobilities due to the different collision cross collision sections of (D-Pen+beta-CD + Li)+ and (L-Pen+beta-CD + Li)+. Penicillamine 38-41 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 42-49 34625257-7 2021 We found that non-covalent complexes (Pen+beta-CD + Li)+ could be easily formed by electrospray ionization of the mixture of the solution, and the chirality of Pen could be effectively recognized by measuring their mobilities due to the different collision cross collision sections of (D-Pen+beta-CD + Li)+ and (L-Pen+beta-CD + Li)+. Penicillamine 286-291 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 42-49 34625257-7 2021 We found that non-covalent complexes (Pen+beta-CD + Li)+ could be easily formed by electrospray ionization of the mixture of the solution, and the chirality of Pen could be effectively recognized by measuring their mobilities due to the different collision cross collision sections of (D-Pen+beta-CD + Li)+ and (L-Pen+beta-CD + Li)+. Penicillamine 286-291 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 292-299 34342310-1 2021 Herein, we designed a diversified sensing platform for d-penicillamine based on amino-functionalized Zr-based metal-organic frameworks (UiO-66-NH2 MOFs) and 3-aminophenylboronic acid (APBA)@Alizarin Red (ARS). Penicillamine 55-70 RIEG2 Homo sapiens 204-207 34288528-3 2021 The reactions of fac-(Ir(aet)3) with Ag+ and penicillamine produced (Ag46S13{Ir(aet)3}14)20+ ((1)20+), where a spherical AgI46S13 cluster is covered by fac-(Ir(aet)3) octahedra through thiolato bridges. Penicillamine 45-58 FA complementation group C Homo sapiens 17-20 34288528-3 2021 The reactions of fac-(Ir(aet)3) with Ag+ and penicillamine produced (Ag46S13{Ir(aet)3}14)20+ ((1)20+), where a spherical AgI46S13 cluster is covered by fac-(Ir(aet)3) octahedra through thiolato bridges. Penicillamine 45-58 FA complementation group C Homo sapiens 152-155 34342310-6 2021 Nevertheless, when d-penicillamine and copper ions coexist in the APBA and Alizarin Red reaction system, the copper ions would complex with the sulfhydryl group of d-penicillamine and no longer hinder the generation of APBA@ARS, and the fluorescence of UiO-66-NH2 MOFs is quenched again. Penicillamine 19-34 RIEG2 Homo sapiens 224-227 34071639-0 2021 D-Penicillamine: The State of the Art in Humans and in Dogs from a Pharmacological and Regulatory Perspective. Penicillamine 0-15 artemin Homo sapiens 34-37 35550750-0 2022 Simultaneous electrochemical recognition of tryptophan and penicillamine enantiomers based on MOF-modified beta-CD. Penicillamine 59-72 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 107-114 35550750-3 2022 The proposed multichiral beta-CD@Ca-sacc/MeOH/GCE can be used for recognition of tryptophan and penicillamine enantiomers simultaneously with wide linear range, low detection limits value, high repeatability and stability within the available electrochemical window. Penicillamine 96-109 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 25-32 35191669-0 2022 Molecular Basis for the Interaction of Catalase with d-Penicillamine: Rationalization of Some of Its Deleterious Effects. Penicillamine 53-68 catalase Homo sapiens 39-47 35426958-0 2022 Sensitive recognition of prostate specific antigen using biotinylated antibody encapsulated on D-penicillamine decorated wrinkled silicate nanoparticles (WSN): An innovative sandwich type biosensor towards diagnosis of prostate cancer. Penicillamine 95-110 kallikrein related peptidase 3 Homo sapiens 25-50 35426958-1 2022 In this study, a new sandwich type biosensor was developed to specific recognition of prostate specific antigen (PSA) and early-stage diagnosis of prostate cancer using encapsulation of biotinylated antibody (Ab1) of prostate specific antigen on D-penicillamine decorated wrinkled silicate nanoparticles (WSN). Penicillamine 246-261 kallikrein related peptidase 3 Homo sapiens 86-111 35426958-1 2022 In this study, a new sandwich type biosensor was developed to specific recognition of prostate specific antigen (PSA) and early-stage diagnosis of prostate cancer using encapsulation of biotinylated antibody (Ab1) of prostate specific antigen on D-penicillamine decorated wrinkled silicate nanoparticles (WSN). Penicillamine 246-261 kallikrein related peptidase 3 Homo sapiens 113-116 35426958-1 2022 In this study, a new sandwich type biosensor was developed to specific recognition of prostate specific antigen (PSA) and early-stage diagnosis of prostate cancer using encapsulation of biotinylated antibody (Ab1) of prostate specific antigen on D-penicillamine decorated wrinkled silicate nanoparticles (WSN). Penicillamine 246-261 kallikrein related peptidase 3 Homo sapiens 217-242 35191669-1 2022 d-Penicillamine (d-Pen) is a sulfur compound used in the management of rheumatoid arthritis, Wilson"s disease (WD), and alcohol dependence. Penicillamine 0-15 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 19-22 2557847-0 1989 Apparent inactivation of alpha 1-antiproteinase by sulphur-containing radicals derived from penicillamine. Penicillamine 92-105 serpin family A member 1 Homo sapiens 25-47 2557847-3 1989 Inactivation of alpha 1-antiproteinase by radiolytically-generated .OH under anoxic conditions was decreased by adding a range of anti-inflammatory drugs to the reaction mixtures, including the thiol compound penicillamine. Penicillamine 209-222 serpin family A member 1 Homo sapiens 16-38 2557847-5 1989 It is proposed that sulphur-containing radicals resulting from attack of biologically-produced oxidants upon penicillamine in the presence of O2 can themselves inactivate alpha 1-antiproteinase, and that such radicals might contribute to the side-effects produced by penicillamine or gold thiol therapy in rheumatoid arthritis. Penicillamine 109-122 serpin family A member 1 Homo sapiens 171-193 2557847-5 1989 It is proposed that sulphur-containing radicals resulting from attack of biologically-produced oxidants upon penicillamine in the presence of O2 can themselves inactivate alpha 1-antiproteinase, and that such radicals might contribute to the side-effects produced by penicillamine or gold thiol therapy in rheumatoid arthritis. Penicillamine 267-280 serpin family A member 1 Homo sapiens 171-193 2514724-7 1989 The Pb-induced inhibition of blood delta-aminolevulinic acid dehydratase activity and the increase in urinary excretion of delta-aminolevulinic acid were reversed to a certain extent by CaNa2EDTA, DPA, and methionine but the combination did not improve their individual performances. Penicillamine 197-200 aminolevulinate dehydratase Rattus norvegicus 35-72 2634884-7 1989 HLA-A 2 or Cw 7-positive patients with RA experienced a low frequency of side effects from penicillamine (12% vs 49% of A 2-negative patients: p less than 0.01, 17% vs 46% of Cw 7-negative patients: p less than 0.05). Penicillamine 91-104 major histocompatibility complex, class I, A Homo sapiens 0-5 2591110-4 1989 On the contrary, a stereological analysis showed that the elastin volume density was higher in patients than in controls, and increased again after D-penicillamine treatment: moreover, the number of elastin fibers per unit area was significantly higher in the dermis of patients compared to controls, and became even higher after D-penicillamine treatment. Penicillamine 148-163 elastin Homo sapiens 58-65 2556228-1 1989 We have demonstrated that penicillamine (PSH) has the capacity to effect phagocytic cells by its interaction with the myeloperoxidase-halide system (MPOHS). Penicillamine 26-39 myeloperoxidase Homo sapiens 118-133 2591110-4 1989 On the contrary, a stereological analysis showed that the elastin volume density was higher in patients than in controls, and increased again after D-penicillamine treatment: moreover, the number of elastin fibers per unit area was significantly higher in the dermis of patients compared to controls, and became even higher after D-penicillamine treatment. Penicillamine 148-163 elastin Homo sapiens 199-206 2591110-4 1989 On the contrary, a stereological analysis showed that the elastin volume density was higher in patients than in controls, and increased again after D-penicillamine treatment: moreover, the number of elastin fibers per unit area was significantly higher in the dermis of patients compared to controls, and became even higher after D-penicillamine treatment. Penicillamine 330-345 elastin Homo sapiens 58-65 2591110-4 1989 On the contrary, a stereological analysis showed that the elastin volume density was higher in patients than in controls, and increased again after D-penicillamine treatment: moreover, the number of elastin fibers per unit area was significantly higher in the dermis of patients compared to controls, and became even higher after D-penicillamine treatment. Penicillamine 330-345 elastin Homo sapiens 199-206 2591110-5 1989 The phenomena were evident in all strata of the dermis; however, the most significant increase of elastin in SSc patients compared to controls was in the superficial dermis, whereas after D-penicillamine treatment, all the strata of the dermis showed a significant increase in the percentage of elastin and in the number of elastin fibers per unit area compared to untreated patients and to controls. Penicillamine 188-203 elastin Homo sapiens 98-105 2591110-5 1989 The phenomena were evident in all strata of the dermis; however, the most significant increase of elastin in SSc patients compared to controls was in the superficial dermis, whereas after D-penicillamine treatment, all the strata of the dermis showed a significant increase in the percentage of elastin and in the number of elastin fibers per unit area compared to untreated patients and to controls. Penicillamine 188-203 elastin Homo sapiens 295-302 2591110-5 1989 The phenomena were evident in all strata of the dermis; however, the most significant increase of elastin in SSc patients compared to controls was in the superficial dermis, whereas after D-penicillamine treatment, all the strata of the dermis showed a significant increase in the percentage of elastin and in the number of elastin fibers per unit area compared to untreated patients and to controls. Penicillamine 188-203 elastin Homo sapiens 295-302 2591110-11 1989 After D-penicillamine, elastin fibers became even more numerous and smaller than in untreated patients. Penicillamine 6-21 elastin Homo sapiens 23-30 2785792-6 1989 Penicillamine and cysteine are more reactive with the C4A isotype than with the C4B isotype of the HLA class III protein C4. Penicillamine 0-13 complement C4A (Rodgers blood group) Homo sapiens 54-57 2668158-4 1989 Similar potentiation of Con A-induced IL-2 release was obtained with D-penicillamine, 1 microM-1 mM, and with the angiotensin-converting enzyme-inhibitor captopril, 10 nM-1 microM. Penicillamine 69-84 interleukin 2 Mus musculus 38-42 2785792-6 1989 Penicillamine and cysteine are more reactive with the C4A isotype than with the C4B isotype of the HLA class III protein C4. Penicillamine 0-13 complement C4B (Chido blood group) Homo sapiens 80-83 2642250-4 1989 Furthermore, it was found that superoxide anion generation was slightly increased, and beta-glucuronidase release markedly increased by preincubation with DPA at concentrations of 0.5-5 mM. Penicillamine 155-158 glucuronidase beta Homo sapiens 87-105 2650036-2 1989 DR3 antigen-positive subjects and poor sulphoxidators are at higher risk than other patients when treated with gold salts or D-penicillamine. Penicillamine 125-140 TNF receptor superfamily member 25 Homo sapiens 0-3 2784082-0 1989 Variation in alpha-1-antitrypsin phenotypes associated with penicillamine therapy. Penicillamine 60-73 serpin family A member 1 Homo sapiens 13-32 2784082-1 1989 During a detailed study of alpha-1-antitrypsin (AAT) by isoelectric focusing, of 130 individuals of the PiZ phenotype and their families, an unusual alpha-1-antitrypsin protein pattern was identified which related directly to the effect of penicillamine therapy. Penicillamine 240-253 serpin family A member 1 Homo sapiens 27-46 2784082-1 1989 During a detailed study of alpha-1-antitrypsin (AAT) by isoelectric focusing, of 130 individuals of the PiZ phenotype and their families, an unusual alpha-1-antitrypsin protein pattern was identified which related directly to the effect of penicillamine therapy. Penicillamine 240-253 serpin family A member 1 Homo sapiens 149-168 3219994-5 1988 PA derivatives suppressed adjuvant-induced arthritis in SD and Lewis rats, suppressed delayed-type hypersensitivity and IgE antibody response in mice, and prolonged the survival time of NZBXNZW F1 hybrid (BWF1) mice, as did immunosuppressors. Penicillamine 0-2 WD repeat and FYVE domain containing 3 Mus musculus 205-209 2782197-6 1989 HLA B8 and/or DR3 alloantigens were identified in 64% of the gold treated and 56% of the penicillamine treated patients. Penicillamine 89-102 TNF receptor superfamily member 25 Homo sapiens 14-17 2702608-2 1989 However, penicillamine binds to precursors of intermolecular crosslinks both in collagen and elastin, and could lead to alterations of these two fibrous proteins. Penicillamine 9-22 elastin Homo sapiens 93-100 2702608-11 1989 The results indicate that prolonged administration of penicillamine to humans induces alterations in the deposition of dermal collagen and elastin. Penicillamine 54-67 elastin Homo sapiens 139-146 3266995-7 1988 D-penicillamine, given in the majority of patients in both groups, produced adverse reactions in 72% of the anti-Ro(SSA) positive patients, but only in 27% of the negative ones. Penicillamine 0-15 tripartite motif containing 21 Homo sapiens 116-119 3266995-8 1988 Thus, anti-Ro(SSA) antibodies seem to characterize a distinct group of RA patients who are almost exclusively female, express more activated B-cell function, have a high prevalence of Sjogren"s features and commonly develop side effects to D-penicillamine. Penicillamine 240-255 tripartite motif containing 21 Homo sapiens 14-17 3135996-5 1988 Under therapy with d-penicillamine the frontal P300-positivity moved from frontal to parietal structures. Penicillamine 19-34 E1A binding protein p300 Homo sapiens 47-51 3145222-0 1988 [Effect of penicillin and D-penicillamine on beta-galactosidase activity in patients with progressive scleroderma]. Penicillamine 26-41 galactosidase beta 1 Homo sapiens 45-63 3136089-8 1988 In the penicillamine group B2MIGLO excretion into urine correlated (p less than 0.01) with PGE2 excretion in the daytime. Penicillamine 7-20 beta-2-microglobulin Homo sapiens 27-34 2975107-2 1988 The results indicate that D-Penicillamine in synergism with copper or ceruloplasmin in vitro inhibits the proliferation of T-lymphocytes and the activity of helper T-cells in supporting the generation of antibody-forming cells. Penicillamine 26-41 ceruloplasmin Homo sapiens 70-83 3063003-1 1988 D-penicillamine (DPA) leads to side effects in different ways: collagen and elastin crosslinking are inhibited, which results in thin and vulnerable skin, cutis laxa, elastosis perforans serpiginosa, wound healing defects and embryopathy. Penicillamine 0-15 elastin Homo sapiens 76-83 3063003-1 1988 D-penicillamine (DPA) leads to side effects in different ways: collagen and elastin crosslinking are inhibited, which results in thin and vulnerable skin, cutis laxa, elastosis perforans serpiginosa, wound healing defects and embryopathy. Penicillamine 17-20 elastin Homo sapiens 76-83 3501473-8 1987 D-penicillamine PM/DM is associated with HLA-B18, B35 and DR4 and is immunogenetically different from idiopathic PM/DM, rheumatoid arthritis and D-penicillamine myasthenia gravis. Penicillamine 0-15 major histocompatibility complex, class II, DR beta 4 Homo sapiens 58-61 2820969-5 1987 Using 2 nM [3H][D-Pen2,D-Pen5]enkephalin (where Pen represents penicillamine) to label delta-sites, 50% loss of sites occurred at about 3 microM DALCE. Penicillamine 63-76 proenkephalin Rattus norvegicus 30-40 2444302-0 1987 The relationship between the complex of immunoglobulin A and alpha-1-antitrypsin, its constituent components and the acute-phase response as measured by C-reactive protein in rheumatoid arthritis treated with gold or D-penicillamine. Penicillamine 217-232 CD79a molecule Homo sapiens 40-56 3687583-4 1987 Regarding the acute phase response, dexamethasone and D-penicillamine appeared to lower and indomethacin and cyclophosphamide to elevate, serum levels of haptoglobin, but these effects were not statistically significant. Penicillamine 54-69 haptoglobin Mus musculus 154-165 3602943-1 1987 The bioavailability of D-penicillamine was measured in 24 patients with generalized scleroderma (Progressive Systemic Sclerosis, PSS). Penicillamine 23-38 PSS Homo sapiens 129-132 3030427-0 1987 The effect of D-penicillamine on myeloperoxidase: formation of compound III and inhibition of the chlorinating activity. Penicillamine 14-29 myeloperoxidase Homo sapiens 33-48 3030427-1 1987 The inhibitory effect of the anti-arthritic drug D-penicillamine on the formation of hypochlorite (HOCl) by myeloperoxidase from H2O2 and Cl- was investigated. Penicillamine 49-64 myeloperoxidase Homo sapiens 108-123 3030427-2 1987 When D-penicillamine was added to myeloperoxidase under turnover conditions, Compound III was formed, the superoxide derivative of the enzyme. Penicillamine 5-20 myeloperoxidase Homo sapiens 34-49 3030427-8 1987 This conclusion is supported by experiments which showed that formation of Compound III of myeloperoxidase by D-penicillamine depended on the chloride concentration. Penicillamine 110-125 myeloperoxidase Homo sapiens 91-106 3030427-11 1987 From the results described in this paper it is proposed that D-penicillamine may exert its therapeutic effect in the treatment of rheumatoid arthritis by scavenging HOCl and by converting myeloperoxidase to Compound III, which is inactive in the formation of HOCl. Penicillamine 61-76 myeloperoxidase Homo sapiens 188-203 2885985-1 1987 The efficiency of sulphasalazine (SASP) as a long-acting antirheumatic drug for rheumatoid arthritis is now well established by placebo-controlled studies and comparative trials with injectable gold and D-penicillamin. Penicillamine 203-217 aspartic peptidase retroviral like 1 Homo sapiens 34-38 3495717-0 1987 Association of HLA DR1 with high D-penicillamine binding to monocytes in females. Penicillamine 33-48 down-regulator of transcription 1 Homo sapiens 19-22 3495717-1 1987 Binding of D-Penicillamine (D-Pen) to human monocytes was examined by flow cytometry with fluorescent D-Pen conjugate. Penicillamine 11-26 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 30-33 2876639-5 1986 The results showed that penicillamine induced relevant modifications in the process of elastin fibrogenesis. Penicillamine 24-37 elastin Gallus gallus 87-94 2876639-7 1986 Interestingly, penicillamine induced the formation of numerous bundles of microfibrils associated or not with elastin fibers. Penicillamine 15-28 elastin Gallus gallus 110-117 3015056-7 1986 During treatment with chloroquine or penicillamine serum osteocalcin increased significantly, concomitant with a reduction of the acute phase reactants. Penicillamine 37-50 bone gamma-carboxyglutamate protein Homo sapiens 57-68 3771100-3 1986 It was found that dPen1TA and dPen1Pen6TA, both of which have a beta,beta-dimethyl-beta-mercaptopropionic acid in position 1, are strong inhibitors of the uterine activity of oxytocin in vitro (without Mg2+) with pA2 values of 7.1 and 7.8, respectively, whereas dPen6TA with penicillamine in position 6 is a mild agonist. Penicillamine 275-288 anterior pharynx defective 1 Drosophila melanogaster 30-41 3133153-0 1986 HLA-A,-B, and -DR antigens in relation to gold and D-penicillamine toxicity in Greek patients with RA. Penicillamine 53-66 major histocompatibility complex, class I, A Homo sapiens 0-17 3954958-0 1986 Collagen and elastin changes in D-penicillamine-induced pseudoxanthoma elasticum-like skin. Penicillamine 32-47 elastin Homo sapiens 13-20 3948434-1 1986 Long-term therapy of D-penicillamine (D-Pen) for rheumatoid arthritis (RA) is associated with a fall in rheumatoid factor, but many patients develop autoantibodies. Penicillamine 21-36 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 40-43 3459889-2 1986 There was a significant association between proteinuria induced by D-penicillamine and the antigens DR3 and B8. Penicillamine 67-82 TNF receptor superfamily member 25 Homo sapiens 100-103 3459889-4 1986 Thrombocytopenia from D-penicillamine was significantly associated with HLA-A1 and DR4; 15 of 23 patients who possessed both antigens developed thrombocytopenia (p less than 0.001 uncorrected, approximate relative risk (RR) = 5.5). Penicillamine 22-37 major histocompatibility complex, class II, DR beta 4 Homo sapiens 83-86 3459889-5 1986 A null complement allele located at the C4B locus (C4BQO) was also associated with thrombocytopenia from D-penicillamine (p less than 0.005, RR = 17.3). Penicillamine 105-120 complement C4B (Chido blood group) Homo sapiens 40-43 3940490-0 1986 Penicillamine-induced insulin antibodies. Penicillamine 0-13 insulin Homo sapiens 22-29 3017877-1 1986 Collagen production was investigated in cultured rabbit synovial fibroblasts exposed in vitro to D-penicillamine (D-Pen). Penicillamine 97-112 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 116-119 3958085-1 1986 A rapid and precise high-performance liquid chromatographic assay for both N-acetylcysteine and penicillamine in blood samples is described using selective reductive electrochemical detection and a high-efficiency C18 reversed-phase column. Penicillamine 96-109 Bardet-Biedl syndrome 9 Homo sapiens 214-217 3932615-10 1985 Catalase activities in liver homogenates were only significantly altered by penicillamine; the highest dose caused the activity to be higher than that in saline-treated chicks. Penicillamine 76-89 catalase Gallus gallus 0-8 2415613-0 1986 Specific sensitization of Lyt-1+2- T cells to spleen cells modified by the drug D-penicillamine or a stereoisomer. Penicillamine 80-95 CD5 antigen Mus musculus 26-31 2415613-1 1986 A mouse model for assessing the sensitization of T cells to the drug D-penicillamine (D-Pen) has been established. Penicillamine 69-84 proprotein convertase subtilisin/kexin type 1 inhibitor Mus musculus 88-91 3095769-7 1986 A six month course of phenobarbital-, cholestyramine- and D-penicillamine-therapy led to significant improvement of cholestasis, however Somatomedin C values and growth velocity remained unchanged. Penicillamine 58-73 insulin like growth factor 1 Homo sapiens 137-150 2998407-3 1985 Hypochlorite, the reactive product of the reaction catalyzed by myeloperoxidase, was effectively scavenged by these antiarthritic drugs, and in addition, D-penicillamine and tiopronin inhibited myeloperoxidase itself. Penicillamine 154-169 myeloperoxidase Homo sapiens 64-79 2998407-3 1985 Hypochlorite, the reactive product of the reaction catalyzed by myeloperoxidase, was effectively scavenged by these antiarthritic drugs, and in addition, D-penicillamine and tiopronin inhibited myeloperoxidase itself. Penicillamine 154-169 myeloperoxidase Homo sapiens 194-209 4064588-3 1985 Comparison between the groups suggests that CRP correlates best with ESR in patients treated with penicillamine and in patients in clinical remission. Penicillamine 98-111 C-reactive protein Homo sapiens 44-47 3929421-5 1985 In the latter group the prevalence of antigen DR4 was high, especially in the patient group with DP-induced thrombocytopenia, all 12 patients with this type of reaction being DR4 positive. Penicillamine 97-99 major histocompatibility complex, class II, DR beta 4 Homo sapiens 46-49 3929421-5 1985 In the latter group the prevalence of antigen DR4 was high, especially in the patient group with DP-induced thrombocytopenia, all 12 patients with this type of reaction being DR4 positive. Penicillamine 97-99 major histocompatibility complex, class II, DR beta 4 Homo sapiens 175-178 3993664-0 1985 Insulin antibodies in patients receiving penicillamine. Penicillamine 41-54 insulin Homo sapiens 0-7 3993664-1 1985 In a patient receiving penicillamine for treatment of rheumatoid arthritis, antibodies to insulin developed, which resulted in symptomatic hypoglycemia. Penicillamine 23-36 insulin Homo sapiens 90-97 3993664-2 1985 When 30 additional patients receiving penicillamine were screened, another patient was discovered to have antibodies to insulin. Penicillamine 38-51 insulin Homo sapiens 120-127 2991870-1 1985 A 27 year old woman with hepato-lenticular degeneration (Wilson"s disease) was found to have primary hepatocellular carcinoma (PHC) three and a half years after she was started on treatment with D-penicillamine. Penicillamine 195-210 immunoglobulin kappa variable 3-20 Homo sapiens 0-4 2859902-4 1985 We conclude that during treatment of rheumatoid arthritis with gold, penicillamine or sulphasalazine, SAA concentrations can be high when serum CRP and ESR are suppressed. Penicillamine 69-82 serum amyloid A1 Homo sapiens 102-105 2859902-4 1985 We conclude that during treatment of rheumatoid arthritis with gold, penicillamine or sulphasalazine, SAA concentrations can be high when serum CRP and ESR are suppressed. Penicillamine 69-82 C-reactive protein Homo sapiens 144-147 2864245-10 1985 Data on the distribution of cross-linking amino acids in elastin samples were also consistent with previous suggestions that impaired cross-linking observed in copper deficiency or from DPA treatment results from different mechanisms. Penicillamine 186-189 elastin Rattus norvegicus 57-64 3977943-0 1985 Difference circular dichroism studies of copper and nickel binding to D-penicillamine in the presence of human serum albumin. Penicillamine 70-85 albumin Homo sapiens 111-124 3977943-1 1985 The binding of copper and nickel to D-penicillamine in the presence of human serum albumin (HSA) has been studied using difference circular dichroism (CD). Penicillamine 36-51 albumin Homo sapiens 77-90 3884477-6 1985 D-penicillamine treatment significantly (p less than 0.01) but transiently reduced beta 2 mu levels in PBC; this may reflect the presumed immunosuppressive action of this drug. Penicillamine 0-15 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 83-89 3844938-3 1985 Incubation of the high molecular weight product with either glutathione or D-penicillamine yielded Fab- and Fc-like fragments. Penicillamine 75-90 FA complementation group B Homo sapiens 99-102 2934220-4 1985 Penicillamine, which prevents the formation of desmosine crosslinks by binding to precursors, induced the production of numerous new elastin fibers which appeared normal from the ultrastructural point of view. Penicillamine 0-13 elastin Gallus gallus 133-140 2934220-7 1985 Moreover, the elastin deposited during beta-APN treatment was always permeated by cytochemically revealed proteoglycans, which were never observed after penicillamine treatment. Penicillamine 153-166 elastin Gallus gallus 14-21 2864680-1 1985 The somatostatin analogs D-Phe-Cys-D-Trp-Lys-Thr-Cys-Thr and the corresponding penicillamine compounds have been prepared and tested for their ability to displace [3H]naloxone and [3H] [D-Ala2, D-Leu5]enkephalin from rat brain receptors. Penicillamine 79-92 proenkephalin Rattus norvegicus 201-211 3871932-7 1985 A third genetic susceptibility to this disease was recently described in patients treated with D-penicillamine, the antigenic frequency of HLA-Bw35, DR1 is significantly increased. Penicillamine 95-110 down-regulator of transcription 1 Homo sapiens 149-152 4070260-0 1985 Is penicillamine transported into cells via system ASC, an amino acid transporter? Penicillamine 3-16 PYD and CARD domain containing Homo sapiens 51-54 6525203-5 1984 The pharmacological relevance of dopamine beta-hydroxylase inhibition by penicillamine is also discussed. Penicillamine 73-86 dopamine beta-hydroxylase Homo sapiens 33-58 6095920-5 1984 Taurine, which in the presence of myeloperoxidase-H2O2-Cl forms hydrophilic chloramines, and D-penicillamine, which scavenges HOCl, neutralize the inhibitory effect of myeloperoxidase. Penicillamine 93-108 myeloperoxidase Homo sapiens 168-183 6334741-0 1984 D-Penicillamine induced toxicity in rheumatoid arthritis: the role of sulphoxidation status and HLA-DR3. Penicillamine 0-15 TNF receptor superfamily member 25 Homo sapiens 100-103 6334696-6 1984 A review of the HLA antigen frequencies in other races and in D-penicillamine (D-Pen) induced MG suggests that prior claims implicating immune response genes marked by DR3 require review. Penicillamine 62-77 TNF receptor superfamily member 25 Homo sapiens 168-171 6334696-6 1984 A review of the HLA antigen frequencies in other races and in D-penicillamine (D-Pen) induced MG suggests that prior claims implicating immune response genes marked by DR3 require review. Penicillamine 79-84 TNF receptor superfamily member 25 Homo sapiens 168-171 6439866-2 1984 Patients with 2 or more side effects to gold and/or penicillamine had a significantly increased frequency of antigens HLA-B8 and DR3 compared to patients with one or without adverse reactions. Penicillamine 52-65 TNF receptor superfamily member 25 Homo sapiens 129-132 6439866-3 1984 Proteinuria to gold or penicillamine was significantly associated with HLA-B8 (relative risk [RR] 4.2) and DR3 (RR 14.0) whereas nonnephrologic side effects to gold or penicillamine were associated with B7 and DR2 (RR 3.5 and 2.8). Penicillamine 23-36 TNF receptor superfamily member 25 Homo sapiens 107-110 6477673-8 1984 It is proposed that aortic smooth muscle cells are activated by an increased pulsatile distension of the vessel wall secondary to the early effect of D-penicillamine on collagen and elastin. Penicillamine 150-165 elastin Rattus norvegicus 182-189 6608925-0 1984 Antibodies to cellular antigens in Greek patients with autoimmune rheumatic diseases: anti-Ro(SSA) antibody a possible marker of penicillamine-D intolerance. Penicillamine 129-144 tripartite motif containing 21 Homo sapiens 94-97 6484310-2 1984 As based on polyacrylamide disc electrophoresis, inactivation of the testicular isozyme, LDH-X, was almost complete with penicillamine and its disulfide, somewhat less with GSH and GSSG, least with thioglycolate and its disulfide and inconsistent with cysteine, 2-mercaptoethanol and 2-mercaptoethylamine. Penicillamine 121-134 lactate dehydrogenase C Homo sapiens 89-94 6328567-5 1984 For the first 2 months after irradiation, penicillamine-treated animals exhibited significantly (P less than 0.05) higher activities of both ACE and PLA than did untreated rats. Penicillamine 42-55 angiotensin I converting enzyme Rattus norvegicus 141-144 6334465-4 1984 In addition, positive ANF were found in 22 of the 62 patients (35.5 p. 100) who had negative ANF before D-Penicillamine therapy. Penicillamine 104-119 natriuretic peptide A Homo sapiens 22-25 6701446-0 1984 Effect of long-term penicillamine therapy on erythrocyte CuZn superoxide dismutase activity. Penicillamine 20-33 superoxide dismutase 1 Homo sapiens 57-82 6701446-1 1984 The effect of long-term penicillamine therapy on erythrocyte CuZn superoxide dismutase activity was investigated. Penicillamine 24-37 superoxide dismutase 1 Homo sapiens 61-86 6701446-3 1984 Seven of the 11 penicillamine-treated patients had CuZn superoxide dismutase activities below the reference interval of the parameter. Penicillamine 16-29 superoxide dismutase 1 Homo sapiens 51-76 6701446-6 1984 Whereas among the penicillamine-treated patients there was a good correlation between serum ceruloplasmin and serum copper, the correlation between these parameters and erythrocyte CuZn superoxide dismutase was only fair. Penicillamine 18-31 ceruloplasmin Homo sapiens 92-105 6701446-7 1984 Erythrocyte CuZn superoxide dismutase is probably a suitable parameter for monitoring intracellular copper availability during penicillamine therapy. Penicillamine 127-140 superoxide dismutase 1 Homo sapiens 12-37 6723122-1 1984 The pharmacokinetic disposition of D-penicillamine and its major metabolites, penicillamine cysteine disulfide ( PSSC ) and penicillamine disulfide ( PSSP ) has been studied in eight patients with rheumatoid arthritis. Penicillamine 35-50 phosphatidylserine decarboxylase Homo sapiens 113-117 6723124-1 1984 The effects of D-penicillamine (D-Pen) in rheumatoid arthritis suggest that the drug may be anti-inflammatory and immunosuppressive. Penicillamine 15-30 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 34-37 6335884-1 1984 L-Histidine (L-His) and human serum albumin (HSA) at physiological concentrations, like the exogenous ligands D-penicillamine (D-PEN) and EDTA, are shown to inhibit the uptake of physiological levels of Ni2+ by B-lymphoblasts of human origin, human erythrocytes and rabbit alveolar macrophages. Penicillamine 110-125 albumin Homo sapiens 30-43 6335884-1 1984 L-Histidine (L-His) and human serum albumin (HSA) at physiological concentrations, like the exogenous ligands D-penicillamine (D-PEN) and EDTA, are shown to inhibit the uptake of physiological levels of Ni2+ by B-lymphoblasts of human origin, human erythrocytes and rabbit alveolar macrophages. Penicillamine 110-125 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 129-132 6606652-16 1984 These results indicate that the mechanism whereby D-penicillamine in the presence of copper or ceruloplasmin inhibits T lymphocyte responsiveness involves the generation of hydrogen peroxide and that other neighboring cells likely to be found w Penicillamine 50-65 ceruloplasmin Homo sapiens 95-108 6230447-1 1983 Different inhibitory effects on the mixed leukocyte reaction were noted with sodium aurothiomalate (GSTM) and D-penicillamine (D-Pen) depending on the lymphocyte/macrophage ratio of responder cell populations. Penicillamine 110-125 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 129-132 6606652-7 1984 The mechanism by which D-penicillamine in the presence of either copper ions or ceruloplasmin caused inhibition of T lymphocyte responsiveness was examined. Penicillamine 23-38 ceruloplasmin Homo sapiens 80-93 6606652-9 1984 While superoxide dismutase had no protective effect, catalase was found to protect lymphocyte responsiveness totally from the inhibitory action of D-penicillamine and either copper ions or ceruloplasmin. Penicillamine 147-162 catalase Homo sapiens 53-61 6324512-5 1984 The effect of gold salts was uncertain and D-penicillamine only inhibited the release of myeloperoxidase. Penicillamine 43-58 myeloperoxidase Homo sapiens 89-104 6315067-0 1983 The effect of D-penicillamine on human myeloperoxidase, a mechanism for the efficacy of the drug in rheumatoid arthritis. Penicillamine 14-29 myeloperoxidase Homo sapiens 39-54 6315067-1 1983 We investigated the effect of D-penicillamine on the ability of myeloperoxidase, purified from human leukocytes, to catalyse the oxidation of chloride ions to hypochlorite (HOCl) in the presence of H2O2. Penicillamine 30-45 myeloperoxidase Homo sapiens 64-79 6315067-2 1983 It is shown that, due to the interaction of D-penicillamine with both myeloperoxidase itself and HOCl, the chlorinating activity of myeloperoxidase in the presence of H2O2 and chloride ions is prevented. Penicillamine 44-59 myeloperoxidase Homo sapiens 70-85 6315067-2 1983 It is shown that, due to the interaction of D-penicillamine with both myeloperoxidase itself and HOCl, the chlorinating activity of myeloperoxidase in the presence of H2O2 and chloride ions is prevented. Penicillamine 44-59 myeloperoxidase Homo sapiens 132-147 6315067-3 1983 A concentration of 100 microM D-penicillamine inhibits the chlorinating activity of myeloperoxidase completely, which Is due to the stabilization of Compound II, an inactive form of the enzyme. Penicillamine 30-45 myeloperoxidase Homo sapiens 84-99 6315067-6 1983 Lower concentrations of D-penicillamine (10 microM) inhibited myeloperoxidase less, but still acted as effective scavengers of HOCl. Penicillamine 24-39 myeloperoxidase Homo sapiens 62-77 6315067-7 1983 In very low concentrations (1 microM), D-penicillamine did not scavenge HOCl effectively, but rather stimulated the chlorinating activity of myeloperoxidase. Penicillamine 39-54 myeloperoxidase Homo sapiens 141-156 6666578-10 1983 These observations support the hypothesis that treatment with high doses of D-pen may induce a fibroproliferative response in rat aorta, possibly by an inhibitory effect on the cross-linking of collagen and elastin. Penicillamine 76-81 elastin Rattus norvegicus 207-214 6871074-0 1983 Conversion in vitro of urinary (+)-penicillamine to its major metabolites, PSSP and PSSC. Penicillamine 31-48 phosphatidylserine decarboxylase Homo sapiens 84-88 6857704-1 1983 The administration of D-penicillamine (450 mg/kg) to young rats resulted in an immediate increase in urinary NAG and volume, as well as mild proteinuria of a predominently low molecular weight type. Penicillamine 22-37 sodium voltage-gated channel alpha subunit 7 Rattus norvegicus 109-112 6304440-1 1983 The enkephalin analogs, [D-Pen2,L-Cys5]- and [D-Pen2,D-Cys5]-enkephalin are cyclic compounds, conformationally constrained by virtue of their 14-membered, disulfide containing rings and by the rigidizing effect of the beta, beta dimethyl substituents of the penicillamine side chain. Penicillamine 258-271 proenkephalin Rattus norvegicus 4-14 6304440-1 1983 The enkephalin analogs, [D-Pen2,L-Cys5]- and [D-Pen2,D-Cys5]-enkephalin are cyclic compounds, conformationally constrained by virtue of their 14-membered, disulfide containing rings and by the rigidizing effect of the beta, beta dimethyl substituents of the penicillamine side chain. Penicillamine 258-271 proenkephalin Rattus norvegicus 61-71 6186262-12 1982 These observations suggest that processes of repair and regeneration are elicited secondary to the inhibitory effect of D-pen on aortic collagen and elastin crosslinking. Penicillamine 120-125 elastin Rattus norvegicus 149-156 6959574-3 1982 In addition 3 out of 4 cases of renal intolerance to D-penicillamine were observed in patients possessing the Cw7 B8 DR3 haplotype. Penicillamine 53-68 TNF receptor superfamily member 25 Homo sapiens 117-120 6812508-4 1982 Penicillamine at high doses enhanced the action of catabolin, while chloroquine inhibited catabolin"s effect on cartilage. Penicillamine 0-13 interleukin 1 beta Homo sapiens 51-60 7185852-1 1982 Long-term high-dosage penicillamine treatment of patients with advanced stages of diseases with autoimmune components has resulted in very few adverse reactions in a series of over 50 such patients also given selected nutrients: pyridoxine, zinc and magnesium (which penicillamine inactivates or chelates), and vitamins B1, B12, and E (which have sulfhydryl-protective activity). Penicillamine 22-35 NADH:ubiquinone oxidoreductase subunit B3 Homo sapiens 324-327 7005521-1 1980 A prospective clinical trial in couples was done to compare effectiveness and toxicity of gold and D-penicillamine (D-Pen.) Penicillamine 99-114 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 118-121 6796481-1 1981 The value of D-penicillamine (D-PA) in the treatment of rheumatoid arthritis is now well established, however, the mode of action remains obscure. Penicillamine 13-28 D-phenylalanine Mus musculus 30-34 6112602-1 1981 The copper-chelating, immunological, and antifibrotic effects of D-penicillamine indicated that it might be suitable for the treatment of primary biliary cirrhosis (PBC). Penicillamine 65-80 dihydrolipoamide S-acetyltransferase Homo sapiens 165-168 6112602-12 1981 Penicillamine treatment is recommended in patients once liver biopsy has demonstrated histological results typical of late stage 3 or 4 PBC. Penicillamine 0-13 dihydrolipoamide S-acetyltransferase Homo sapiens 136-139 7248250-1 1981 [1-Penicillamine,2-leucine]oxytocin is a conformationally restricted analogue of oxytoxin in which the half-cystine-1 and tyrosine-2 residues of the native hormone are replaced by half-penicillamine (beta, beta-dimethyl-half-cystine) and leucine, respectively. Penicillamine 185-198 oxytocin/neurophysin I prepropeptide Homo sapiens 27-35 7248250-6 1981 Extensive proton magnetic resonance experiments were performed to determine the conformational properties of this analogue in aqueous solution, and the results were compared with the previously published model for the conformation of [1-penicillamine]oxytocin. Penicillamine 237-250 oxytocin/neurophysin I prepropeptide Homo sapiens 251-259 7248250-9 1981 One particular result of these conformational differences is that, whereas for [1-penicillamine]oxytocin the tyrosine-2 side chain is unable to assume the rotamer for maximal binding to the uterine receptor, [1-penicillamine,2-leucine]oxytoxin retains conformational and dynamic properties at residues two and three which are more similar to those of oxytocin. Penicillamine 82-95 oxytocin/neurophysin I prepropeptide Homo sapiens 96-104 6105889-5 1980 Similarly, micromolar concentrations of the S-nitroso derivatives of penicillamine, GSH and dithiothreitol, prepared by reacting the thiol with nitric oxide, activated guanylate cyclase. Penicillamine 69-82 guanylate cyclase Bos taurus 168-185 6448425-0 1980 Influence of D-penicillamine and iproniazid on the formation of cross-links in elastin. Penicillamine 13-28 elastin Homo sapiens 79-86 7436556-6 1980 ESR and C-reactive protein were shown to be the most suitable indices of disease improvement with penicillamine treatment. Penicillamine 98-111 C-reactive protein Homo sapiens 8-26 383128-4 1979 The antibacterial activity of milk from sows suckling normal young increased with the lactoperoxidase, and this bactericidal activity could be reversed by LPO inhibitors such as penicillamine and cysteine but not by addition of sufficient iron to saturate the lactoferrin. Penicillamine 178-191 lactoperoxidase Cavia porcellus 155-158 496450-4 1979 The relationship between CRP and ESR was, however, altered by treatment with gold, penicillamine, or high doses of prednisone. Penicillamine 83-96 C-reactive protein Homo sapiens 25-28 554173-4 1979 On the other hand, the ligand exchange reaction between this complex and penicillamine indicates that a low hydrolyzed 99mTc species is coordinated with 2-MPG. Penicillamine 73-86 N-methylpurine-DNA glycosylase Mus musculus 155-158 159271-1 1979 A 2 1/4 year-old boy was treated for cystinuria and urolithiasis with high fluid intake, sodium bicarbonate, and D-penicillamine, over a period of 5 3/4 years, unauthorized interruptions and prescribed pauses included. Penicillamine 113-128 immunoglobulin kappa variable 2-26 (pseudogene) Homo sapiens 0-7 152927-0 1978 Influence of D-penicillamine on the formation of elastin and its cross-links. Penicillamine 13-28 elastin Gallus gallus 49-56 287191-1 1979 The inhibitory effects of D-penicillamine (D-Pen) on lymphocyte activation by PHA are found to be dose-dependent, showing significant effects above a concentration of 50 microgram/ml. Penicillamine 26-41 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 45-48 451491-5 1979 500 microgram/mlD-penicillamine added to skil cultures in vitro inhibited both collagen and general protein synthesis (p less than 0.01). Penicillamine 18-31 SKI like proto-oncogene Homo sapiens 41-45 31141-5 1978 Following treatment with penicillamine, GGTP levels showed a significant drop towards normal levels. Penicillamine 25-38 inactive glutathione hydrolase 2 Homo sapiens 40-44 736410-2 1978 It is hypothesized that decreased copper availability secondary to penicillamine therapy may result in defective elastin within the lamina of Bruch with resultant defects in the overlying retinal pigment epithelium. Penicillamine 67-80 elastin Homo sapiens 113-120 152927-2 1978 D-Penicillamine was shown to alter the formation and maturation of elastin. Penicillamine 0-15 elastin Gallus gallus 67-74 830674-0 1977 Model for the binding of D-penicillamine to metal ions in living systems: Synthesis and structure of L-histidinyl-D-penicillaminatocobalt(III) monohydrate, [Co(L-His)(D-Pen)]-H2O. Penicillamine 25-40 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 169-172 152927-5 1978 On the other hand, a high dose of D-penicillamine (100 mg) decreased the content of elastin and also of its desmosine cross-links. Penicillamine 34-49 elastin Gallus gallus 84-91 152927-6 1978 The authors explain their findings by counteraction of two factors due to administration of penicillamine: the increased solubility of "insoluble elastin", and the decreased cross-link formation. Penicillamine 92-105 elastin Gallus gallus 146-154 415820-0 1977 Interaction of albumin, transferrin, and human serum with indium-113 m complexes of ethylenediaminetetracetic acid, penicillamine, and related compounds. Penicillamine 116-129 transferrin Homo sapiens 24-35 557339-6 1977 When cross-linking was inhibited with penicillamine, the 72 000-dalton component persisted in the tissue 5 h. When cross-linking was inhibited with beta-aminopropionitrile, the elastin component of 72 000 daltons persisted for about 2 h, but thereafter it was gradually degraded to small peptides which were recovered in the incubation medium. Penicillamine 38-51 elastin Gallus gallus 177-184 906929-0 1977 Nutritional copper deficiency and penicillamine administration: some effects on bone collagen and arterial elastin crosslinking. Penicillamine 34-47 elastin Gallus gallus 107-114 409034-5 1977 However, both DP- and NAC-treated cells showed a similar sensitivity to lysis by acid serum and about the same degree of acetylcholinesterase (AChE) activity decrease, thus indicating that the susceptibility to autoxidation of lipids is not involved in the determination of complement sensitivity or in the AChE activity decrease of the sulfydryl-treated cells. Penicillamine 14-16 acetylcholinesterase (Cartwright blood group) Homo sapiens 121-141 409034-5 1977 However, both DP- and NAC-treated cells showed a similar sensitivity to lysis by acid serum and about the same degree of acetylcholinesterase (AChE) activity decrease, thus indicating that the susceptibility to autoxidation of lipids is not involved in the determination of complement sensitivity or in the AChE activity decrease of the sulfydryl-treated cells. Penicillamine 14-16 acetylcholinesterase (Cartwright blood group) Homo sapiens 143-147 409034-5 1977 However, both DP- and NAC-treated cells showed a similar sensitivity to lysis by acid serum and about the same degree of acetylcholinesterase (AChE) activity decrease, thus indicating that the susceptibility to autoxidation of lipids is not involved in the determination of complement sensitivity or in the AChE activity decrease of the sulfydryl-treated cells. Penicillamine 14-16 acetylcholinesterase (Cartwright blood group) Homo sapiens 307-311 906929-8 1977 The administration of penicillamine at different levels to young growing chicks allows the isolation of fibrous insoluble elastin varying in aldehyde content. Penicillamine 22-35 elastin Gallus gallus 122-129 785935-5 1976 Administration of penicillamine to patients with MS resulted in an insignificant lowering of serum IgA, IgG and IgM levels. Penicillamine 18-31 CD79a molecule Homo sapiens 99-102 956895-2 1976 We have studied the effects of these conditions on the formation of the monomer complex that we call Complex I, in which 99mTc is coordinated with the penicillamine as 99mTcO+2. Penicillamine 151-164 cytochrome c oxidase II, mitochondrial Mus musculus 170-176 1266422-0 1976 [Ceruloplasmin and immunoglobulins under controlled D-penicillamine therapy in rheumatoid arthritis]. Penicillamine 52-67 ceruloplasmin Homo sapiens 1-14 1271018-0 1976 The influence of D-penicillamine on enzymatic activities: glucose-6-phosphate dehydrogenase. Penicillamine 17-32 glucose-6-phosphate dehydrogenase Homo sapiens 58-91 1271018-3 1976 In high concentrations, D-penicillamine inhibits glucose-6-phosphate dehydrogenase activity (concentrations above 6.7 mmol/l, i. e. l g/l). Penicillamine 24-39 glucose-6-phosphate dehydrogenase Homo sapiens 49-82 1271018-5 1976 In human skin homogenates, an activating action of D-penicillamine on glucose-6-phosphate dehydrogenase activity occurs due to the chelation of metal ions. Penicillamine 51-66 glucose-6-phosphate dehydrogenase Homo sapiens 70-103 182176-0 1976 Effect of penicillamine on the conversion of dopa to dopachrome in the presence of tyrosinase or ceruloplasmin. Penicillamine 10-23 tyrosinase Homo sapiens 83-93 182176-0 1976 Effect of penicillamine on the conversion of dopa to dopachrome in the presence of tyrosinase or ceruloplasmin. Penicillamine 10-23 ceruloplasmin Homo sapiens 97-110 1085099-1 1976 The D-penicillamine (D-Pen.) Penicillamine 4-19 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 23-26 1200715-3 1975 A dose-dependent activation by D-penicillamine occurred in the case of G-6-PDH- and AcP-activities, a dose-dependent inhibition by D-penicillamine was found with AP- and GAPDH-activities. Penicillamine 31-46 glucose-6-phosphate dehydrogenase Homo sapiens 71-78 1200715-3 1975 A dose-dependent activation by D-penicillamine occurred in the case of G-6-PDH- and AcP-activities, a dose-dependent inhibition by D-penicillamine was found with AP- and GAPDH-activities. Penicillamine 31-46 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 170-175 1200715-3 1975 A dose-dependent activation by D-penicillamine occurred in the case of G-6-PDH- and AcP-activities, a dose-dependent inhibition by D-penicillamine was found with AP- and GAPDH-activities. Penicillamine 131-146 glucose-6-phosphate dehydrogenase Homo sapiens 71-78 1200715-3 1975 A dose-dependent activation by D-penicillamine occurred in the case of G-6-PDH- and AcP-activities, a dose-dependent inhibition by D-penicillamine was found with AP- and GAPDH-activities. Penicillamine 131-146 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 170-175 13869965-0 1961 [The use of penicillamine as a diagnostic aid in hepatolenticular degeneration (Wilson"s disease)]. Penicillamine 12-25 activation induced cytidine deaminase Homo sapiens 42-45 5659685-1 1968 Administration of D-penicillamine and lathyrogens such as beta-amino-propionitrile to animals markedly alters connective tissue by preventing the normal cross-linkage of elastin and collagen. Penicillamine 18-33 elastin Homo sapiens 170-177 5659685-3 1968 We show that penicillamine acts after the initial step, causing the accumulation of an elastin rich in alpha-amino adipic-delta-semialdehyde. Penicillamine 13-26 elastin Homo sapiens 87-94 6026104-4 1967 With penicillamine therapy, ceruloplasmin disappeared from the serum of the first patient; it reappeared after the drug was discontinued. Penicillamine 5-18 ceruloplasmin Homo sapiens 28-41 5922363-0 1966 Influence of penicillamine on the turnover of I-131-labeled ceruloplasmin in Wilson"s disease. Penicillamine 13-26 ceruloplasmin Homo sapiens 60-73 33935689-0 2021 Nasal Delivery of D-Penicillamine Hydrogel Upregulates a Disintegrin and Metalloprotease 10 Expression via Melatonin Receptor 1 in Alzheimer"s Disease Models. Penicillamine 18-33 a disintegrin and metallopeptidase domain 10 Mus musculus 55-91 33636492-1 2021 Herein, fluorescent DNA-templated silver nanoclusters (DNA-AgNCs) with red emission were synthesized and utilized as novel probe to detect D-penicillamine (D-Pen) for the first time. Penicillamine 139-154 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 158-161 33935689-3 2021 D-penicillamine (D-Pen) is a water-soluble metal chelator and can reduce the aggregation of amyloid-beta (Abeta) with metals in vitro. Penicillamine 0-15 proprotein convertase subtilisin/kexin type 1 inhibitor Mus musculus 19-22 33935689-3 2021 D-penicillamine (D-Pen) is a water-soluble metal chelator and can reduce the aggregation of amyloid-beta (Abeta) with metals in vitro. Penicillamine 0-15 amyloid beta (A4) precursor protein Mus musculus 106-111 33310611-4 2021 The diverse encapsulation configurations with different interaction energy show that both D-Pen and L-Pen tend to longitudinally embedded into the narrow aperture of beta-CD with the front part of the sulfur group and the methyl group, and the interaction energy between L-Pen and beta-CD is 5.47 kJ/mol(M062XD3) lower than that between D-Pen and beta-CD. Penicillamine 90-95 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 166-173 33310611-4 2021 The diverse encapsulation configurations with different interaction energy show that both D-Pen and L-Pen tend to longitudinally embedded into the narrow aperture of beta-CD with the front part of the sulfur group and the methyl group, and the interaction energy between L-Pen and beta-CD is 5.47 kJ/mol(M062XD3) lower than that between D-Pen and beta-CD. Penicillamine 90-95 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 281-288 33310611-4 2021 The diverse encapsulation configurations with different interaction energy show that both D-Pen and L-Pen tend to longitudinally embedded into the narrow aperture of beta-CD with the front part of the sulfur group and the methyl group, and the interaction energy between L-Pen and beta-CD is 5.47 kJ/mol(M062XD3) lower than that between D-Pen and beta-CD. Penicillamine 90-95 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 281-288 33310611-4 2021 The diverse encapsulation configurations with different interaction energy show that both D-Pen and L-Pen tend to longitudinally embedded into the narrow aperture of beta-CD with the front part of the sulfur group and the methyl group, and the interaction energy between L-Pen and beta-CD is 5.47 kJ/mol(M062XD3) lower than that between D-Pen and beta-CD. Penicillamine 337-342 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 166-173 33310611-4 2021 The diverse encapsulation configurations with different interaction energy show that both D-Pen and L-Pen tend to longitudinally embedded into the narrow aperture of beta-CD with the front part of the sulfur group and the methyl group, and the interaction energy between L-Pen and beta-CD is 5.47 kJ/mol(M062XD3) lower than that between D-Pen and beta-CD. Penicillamine 337-342 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 281-288 33310611-4 2021 The diverse encapsulation configurations with different interaction energy show that both D-Pen and L-Pen tend to longitudinally embedded into the narrow aperture of beta-CD with the front part of the sulfur group and the methyl group, and the interaction energy between L-Pen and beta-CD is 5.47 kJ/mol(M062XD3) lower than that between D-Pen and beta-CD. Penicillamine 337-342 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 281-288 33310611-8 2021 It is also noted that the H(-OH) in D-Pen and S in L-Pen contribute the most to the intermolecular interaction with beta-CD in comparison with other atoms in Pen. Penicillamine 36-41 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 116-123 33300046-7 2021 Consistently, levels of class III beta-tubulin (Tuj1) and microtubule-associated protein 2 (MAP2) were significantly elevated, whereas glial fibrillary acidic protein (GFAP) levels were obviously suppressed in the presence of GDL or penicillamine. Penicillamine 233-246 glial fibrillary acidic protein Mus musculus 135-166 33352220-3 2021 In this study, we found, interestingly and unexpectedly, that superoxide dismutase (SOD) can significantly shorten the delay of TCHQ autooxidation by penicillamine, but not by ascorbate; SOD can also markedly increase the yields of the oxidized form of penicillamine. Penicillamine 150-163 superoxide dismutase 1 Homo sapiens 62-82 33352220-3 2021 In this study, we found, interestingly and unexpectedly, that superoxide dismutase (SOD) can significantly shorten the delay of TCHQ autooxidation by penicillamine, but not by ascorbate; SOD can also markedly increase the yields of the oxidized form of penicillamine. Penicillamine 150-163 superoxide dismutase 1 Homo sapiens 84-87 33352220-3 2021 In this study, we found, interestingly and unexpectedly, that superoxide dismutase (SOD) can significantly shorten the delay of TCHQ autooxidation by penicillamine, but not by ascorbate; SOD can also markedly increase the yields of the oxidized form of penicillamine. Penicillamine 150-163 superoxide dismutase 1 Homo sapiens 187-190 33352220-3 2021 In this study, we found, interestingly and unexpectedly, that superoxide dismutase (SOD) can significantly shorten the delay of TCHQ autooxidation by penicillamine, but not by ascorbate; SOD can also markedly increase the yields of the oxidized form of penicillamine. Penicillamine 253-266 superoxide dismutase 1 Homo sapiens 62-82 33352220-3 2021 In this study, we found, interestingly and unexpectedly, that superoxide dismutase (SOD) can significantly shorten the delay of TCHQ autooxidation by penicillamine, but not by ascorbate; SOD can also markedly increase the yields of the oxidized form of penicillamine. Penicillamine 253-266 superoxide dismutase 1 Homo sapiens 84-87 33352220-3 2021 In this study, we found, interestingly and unexpectedly, that superoxide dismutase (SOD) can significantly shorten the delay of TCHQ autooxidation by penicillamine, but not by ascorbate; SOD can also markedly increase the yields of the oxidized form of penicillamine. Penicillamine 253-266 superoxide dismutase 1 Homo sapiens 187-190 32825582-3 2020 This study assesses the use of synthetic human tubal fluid (HTF) supplemented with D-penicillamine (HTF + PEN) for the in vitro capacitation of frozen/thawed stallion spermatozoa by examining capacitation-related events over 180 min of incubation. Penicillamine 83-98 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 106-109 32623304-6 2020 It is found that the featured vibrations of [beta-CD + l-Peni + H]+ are more red-shifted than those of [beta-CD + d-Peni + H]+. Penicillamine 114-120 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 45-52 32623304-6 2020 It is found that the featured vibrations of [beta-CD + l-Peni + H]+ are more red-shifted than those of [beta-CD + d-Peni + H]+. Penicillamine 114-120 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 104-111 32623304-7 2020 Through DFT calculations on the complex configurations sampled from molecular dynamics simulations, d-Peni is found embedded inside beta-CD with a lower free energy of 11.5 kJ mol-1 in the lowest configuration than that of the lowest [beta-CD + l-Peni + H]+ configuration, in which l-Peni is found lying upon the beta-CD. Penicillamine 100-106 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 132-139 32623304-7 2020 Through DFT calculations on the complex configurations sampled from molecular dynamics simulations, d-Peni is found embedded inside beta-CD with a lower free energy of 11.5 kJ mol-1 in the lowest configuration than that of the lowest [beta-CD + l-Peni + H]+ configuration, in which l-Peni is found lying upon the beta-CD. Penicillamine 100-106 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 235-242 32623304-7 2020 Through DFT calculations on the complex configurations sampled from molecular dynamics simulations, d-Peni is found embedded inside beta-CD with a lower free energy of 11.5 kJ mol-1 in the lowest configuration than that of the lowest [beta-CD + l-Peni + H]+ configuration, in which l-Peni is found lying upon the beta-CD. Penicillamine 100-106 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 235-242 32905187-9 2020 DPA also protected against Cu2+ (1 mM)-induced inhibition of catalase activity. Penicillamine 0-3 Catalase Drosophila melanogaster 61-69 31985234-8 2020 Surprisingly, in ALDH6A1-O/E cells, NO was decreased nearly 50% but ROS was increased at the similar level, while the former was restored by treatment with S-nitroso-N-acetyl-penicillamine. Penicillamine 156-188 aldehyde dehydrogenase 6 family member A1 Homo sapiens 17-24 32291276-4 2020 After d-penicillamine (D-PCA) therapy, serum aminotransferase and ceruloplasmin levels in this patient were normalized and levels of HbA1c decreased. Penicillamine 6-21 ceruloplasmin Homo sapiens 66-79 32291276-4 2020 After d-penicillamine (D-PCA) therapy, serum aminotransferase and ceruloplasmin levels in this patient were normalized and levels of HbA1c decreased. Penicillamine 23-28 ceruloplasmin Homo sapiens 66-79 30895794-5 2019 Altering the pattern of cysteine and penicillamine generates hundreds of different CDP scaffolds tolerant to extensive sequence manipulations. Penicillamine 37-50 natriuretic peptide A Homo sapiens 83-86 30952240-7 2019 Optimized experimental conditions were used todetermine lipoic acid, tiopronin, and penicillamine, obtaining detection limits of <=1 muM (30 pmol injected). Penicillamine 84-97 latexin Homo sapiens 136-139 31316974-7 2019 The gradient shell and CSS systems could be transferred to the aqueous phase using surface ligand exchange with penicillamine. Penicillamine 112-125 cytidine monophosphate N-acetylneuraminic acid synthetase Homo sapiens 23-26 30680763-2 2019 In this study, penicillamine-protected gold nanoclusters (Pen-AuNCs) were synthesized and initially fractionated by sequential size-selective precipitation (SSSP). Penicillamine 15-28 proprotein convertase subtilisin/kexin type 1 inhibitor Homo sapiens 58-61 29376536-1 2018 Treatment of Lambda-fac-[Co(d-pen-N,S)3]3- (d-H2pen = d-penicillamine) with Cu+ in water gave a stable CoCu complex, LambdaLambda-[Co2Cu3(d-pen)6]3- ([1]3-), having three thiolato-copper(i)-thiolato moieties that bridge two cobalt(iii) centres. Penicillamine 54-69 FA complementation group C Homo sapiens 20-23 30181379-7 2018 The expression of vascular injury factors and ICAM-1, VCAM-1 was significantly increased by WD and markedly decreased in GanDouLing-Penicillamine group. Penicillamine 132-145 intercellular adhesion molecule 1 Mus musculus 46-52 30181379-7 2018 The expression of vascular injury factors and ICAM-1, VCAM-1 was significantly increased by WD and markedly decreased in GanDouLing-Penicillamine group. Penicillamine 132-145 vascular cell adhesion molecule 1 Mus musculus 54-60 30181379-8 2018 The expression of caspase-3, caspase-12, PERK, eIF2alpha, and CHOP were obviously expressed in Wilson group, GanDouLing-Penicillamine suppressed apoptosis and endoplasmic reticulum (ER) stress. Penicillamine 120-133 caspase 3 Mus musculus 18-27 30181379-8 2018 The expression of caspase-3, caspase-12, PERK, eIF2alpha, and CHOP were obviously expressed in Wilson group, GanDouLing-Penicillamine suppressed apoptosis and endoplasmic reticulum (ER) stress. Penicillamine 120-133 caspase 12 Mus musculus 29-39 30181379-8 2018 The expression of caspase-3, caspase-12, PERK, eIF2alpha, and CHOP were obviously expressed in Wilson group, GanDouLing-Penicillamine suppressed apoptosis and endoplasmic reticulum (ER) stress. Penicillamine 120-133 eukaryotic translation initiation factor 2 alpha kinase 3 Mus musculus 41-45 30181379-8 2018 The expression of caspase-3, caspase-12, PERK, eIF2alpha, and CHOP were obviously expressed in Wilson group, GanDouLing-Penicillamine suppressed apoptosis and endoplasmic reticulum (ER) stress. Penicillamine 120-133 eukaryotic translation initiation factor 2A Mus musculus 47-56 30181379-8 2018 The expression of caspase-3, caspase-12, PERK, eIF2alpha, and CHOP were obviously expressed in Wilson group, GanDouLing-Penicillamine suppressed apoptosis and endoplasmic reticulum (ER) stress. Penicillamine 120-133 DNA-damage inducible transcript 3 Mus musculus 62-66 29306821-9 2018 Additionally we have investigated the effect of D-penicillamine, ethylenediaminetetraacetic acid and cadmium chloride on PON1 activities in human serum. Penicillamine 48-63 paraoxonase 1 Homo sapiens 121-125 29306821-10 2018 D-penicillamine and ethylenediaminetetraacetic acid in therapeutic doses as well as cadmium chloride in toxic doses decrease PON1 activities in human serum when compared to non-treated serum. Penicillamine 0-15 paraoxonase 1 Homo sapiens 125-129 29306821-11 2018 D-penicillamine as metal chelator inhibits much stronger PON1 activities than ethylenediaminetetraacetic acid. Penicillamine 0-15 paraoxonase 1 Homo sapiens 57-61 29308818-3 2018 Herein, Cu nanoclusters S1 and Ag(i)-doped Cu/Ag nanoclusters S2 and S3 coated with d-penicillamine are designed and synthesized by a self-assembly strategy. Penicillamine 84-99 proteasome 26S subunit, non-ATPase 1 Homo sapiens 24-45 28551160-6 2017 Treatment with copper chelators (ammonium tetrathiomolybdate, bathocuproinedisulfonic acid and D-penicillamine) increased expression of hCTR1 protein in DLD-1 and SW620 cells, and potentiated the cytotoxicity of oxaliplatin in DLD-1 but not SW620 cells. Penicillamine 95-110 solute carrier family 31 member 1 Homo sapiens 136-141 29675240-4 2018 The orthogonality between beta-thiovaline-Nbz and a conventional alkyl thioester, as well as the convenient access to the former from readily available penicillamine, also allowed expedited assembly of the peptidic hormone beta-LPH and hPTH analogues, based on a kinetically controlled one-pot three-segment ligation and desulfurization strategy. Penicillamine 152-165 proopiomelanocortin Homo sapiens 223-231 29675240-4 2018 The orthogonality between beta-thiovaline-Nbz and a conventional alkyl thioester, as well as the convenient access to the former from readily available penicillamine, also allowed expedited assembly of the peptidic hormone beta-LPH and hPTH analogues, based on a kinetically controlled one-pot three-segment ligation and desulfurization strategy. Penicillamine 152-165 parathyroid hormone Homo sapiens 236-240 28525866-1 2017 B3LYP and MP2 calculations have been carried out to investigate tautomers and enantiomers of penicillamine (Pen). Penicillamine 93-106 tryptase pseudogene 1 Homo sapiens 10-13 31457864-1 2017 We have combined results from several spectroscopic techniques to investigate the aerobic reactions of Rh2(AcO)4 (AcO- = CH3COO-) with l-cysteine (H2Cys) and its derivatives d-penicillamine (3,3"-dimethylcysteine, H2Pen), with steric hindrance at the thiol group, and N-acetyl-l-cysteine (H2NAC), with its amino group blocked. Penicillamine 174-189 Rh associated glycoprotein Homo sapiens 103-112 31457864-1 2017 We have combined results from several spectroscopic techniques to investigate the aerobic reactions of Rh2(AcO)4 (AcO- = CH3COO-) with l-cysteine (H2Cys) and its derivatives d-penicillamine (3,3"-dimethylcysteine, H2Pen), with steric hindrance at the thiol group, and N-acetyl-l-cysteine (H2NAC), with its amino group blocked. Penicillamine 191-212 Rh associated glycoprotein Homo sapiens 103-112 31457864-8 2017 In the cysteine and penicillamine complexes, double thiolate bridges join the Rh(III) ions, with the nonbridging Cys2- and Pen2- ligands in tridentate chelating (S,N,O) mode, which is consistent with the DeltadeltaC = 7.3-8.4 ppm shift of the COO- signal in their carbon-13 cross polarization magic angle spinning (CPMAS) NMR spectra. Penicillamine 20-33 presenilin enhancer, gamma-secretase subunit Homo sapiens 123-127 28749642-0 2017 Combination Therapy with Low Copper Diet, Penicillamine and Gamma Knife Radiosurgery Reduces VEGF and IL-8 In Patients with Recurrent Glioblastoma Purpose: Vascular Endothelial Growth Factor (VEGF) and interleukin-8 (IL-8) appear important in tumor growth. Penicillamine 42-55 C-X-C motif chemokine ligand 8 Homo sapiens 102-106 28749642-9 2017 Discussion: Our results could reflect that low copper diet and penicillamine may decrease serum VEGF inpatients who underwent gamma knife radiosurgery for recurrent glioblastoma multiforme. Penicillamine 63-76 vascular endothelial growth factor A Homo sapiens 96-100 28025393-18 2017 This oxidative stress was prevented by nuclephile D-penicillamine (PEN). Penicillamine 50-65 tetraspanin 33 Homo sapiens 67-70 28071527-6 2017 Silymarin pretreatment and D-penicillamine administration in groups 5, 7 and 8 could significantly lower ALP, ALT and AST and improve liver antioxidant enzymes. Penicillamine 27-42 glutamic-oxaloacetic transaminase 2 Rattus norvegicus 118-121 28460159-3 2017 We have developed a strategy to quantitatively analyze the adsorption and conformational features of transferrin on gold nanoparticles that are functionalized with d, l, and racemic penicillamine. Penicillamine 182-195 transferrin Homo sapiens 101-112 26784915-3 2016 Wilson"s disease is an inborn error of copper metabolism caused by a mutation in the copper transporting gene ATP7B, and traditional treatment is based on copper chelation with agents such as D-penicillamine. Penicillamine 192-207 ATPase copper transporting beta Homo sapiens 110-115 27892672-10 2016 Conclusions: It seems thatreducing the level of copper in the diet and dosing with penicillamine leads to decline of angiogenesis-related factorssuch as VEGF, IL-6 and TNF-alpha. Penicillamine 83-96 vascular endothelial growth factor A Homo sapiens 153-157 27892672-10 2016 Conclusions: It seems thatreducing the level of copper in the diet and dosing with penicillamine leads to decline of angiogenesis-related factorssuch as VEGF, IL-6 and TNF-alpha. Penicillamine 83-96 interleukin 6 Homo sapiens 159-163 27892672-10 2016 Conclusions: It seems thatreducing the level of copper in the diet and dosing with penicillamine leads to decline of angiogenesis-related factorssuch as VEGF, IL-6 and TNF-alpha. Penicillamine 83-96 tumor necrosis factor Homo sapiens 168-177 26890936-0 2016 D-Penicillamine modulates hydrogen sulfide (H2S) pathway through selective inhibition of cystathionine-gamma-lyase. Penicillamine 0-15 cystathionine gamma-lyase Homo sapiens 89-114 26890936-8 2016 In particular, D-penicillamine selectively inhibited CSE in a pyridoxal-5"-phosphate-dependent manner. Penicillamine 15-30 cystathionine gamma-lyase Homo sapiens 53-56 26890936-9 2016 CONCLUSIONS AND IMPLICATIONS: Taken together, our results suggest that D-penicillamine acts as a selective CSE inhibitor, leading to new perspectives in the design and use of specific pharmacological tools for H2 S research. Penicillamine 71-86 cystathionine gamma-lyase Homo sapiens 107-110 26890936-10 2016 In addition, the inhibitory effect of D-penicillamine on CSE could account for its beneficial action in rheumatoid arthritis patients, where H2 S has been shown to have a detrimental effect. Penicillamine 38-53 cystathionine gamma-lyase Homo sapiens 57-60 27122662-0 2016 Functional analysis and drug response to zinc and D-penicillamine in stable ATP7B mutant hepatic cell lines. Penicillamine 50-65 ATPase copper transporting beta Homo sapiens 76-81 27285100-8 2016 By blocking directly or indirectly the desmosine cross-links between elastin molecules, D-penicillamine leads to the synthesis of abnormal dermal and extracutaneous elastic fibers. Penicillamine 88-103 elastin Homo sapiens 69-76 26345691-9 2015 The validity of these findings was then tested through treatment of oxidatively stressed cells with the nucleophile penicillamine in order to scavenge lipid aldehydes and limit their ability to interact with HSPA2. Penicillamine 116-129 heat shock protein family A (Hsp70) member 2 Homo sapiens 208-213 26345691-15 2015 The use of penicillamine enabled a partial recovery of ARSA surface expression and zona pellucida adherence in H2O2-treated cells. Penicillamine 11-24 arylsulfatase A Homo sapiens 55-59 26288416-1 2015 D-penicillamine interferes with elastin and collagen metabolism and produces several cutaneous and multi-systemic side-effects. Penicillamine 0-15 elastin Homo sapiens 32-39 26452863-0 2015 Penicillamine-modified sensor for the voltammetric determination of Cd(II) and Pb(II) ions in natural samples. Penicillamine 0-13 submaxillary gland androgen regulated protein 3B Homo sapiens 68-85 26452863-1 2015 A new penicillamine-GCE was developed based on the immobilization of d-penicillamine on aryl diazonium salt monolayers anchored to the glassy carbon electrode (GCE) surface and it was applied for the first time to the simultaneous determination of Cd(II) and Pb(II) ions by stripping voltammetric techniques. Penicillamine 69-84 submaxillary gland androgen regulated protein 3B Homo sapiens 248-265 25801007-7 2015 D-penicillamine promoted copper influx transporter hCtr1 expression through upregulation of Sp1. Penicillamine 0-15 solute carrier family 31 member 1 Homo sapiens 51-56 25801007-10 2015 Notably, Mice received D-penicillamine alone or in combination of D-penicillamine ad oxalipatin, increased hCtrl protein level in S3 xenograft tumor, however, the protein level of ATP7A was decreased. Penicillamine 23-38 ATPase, Cu++ transporting, alpha polypeptide Mus musculus 180-185 25801007-10 2015 Notably, Mice received D-penicillamine alone or in combination of D-penicillamine ad oxalipatin, increased hCtrl protein level in S3 xenograft tumor, however, the protein level of ATP7A was decreased. Penicillamine 66-81 ATPase, Cu++ transporting, alpha polypeptide Mus musculus 180-185 25801007-11 2015 Taken together, this study provides insight into that the co-manipulation of hCtrl and ATP7A by D-penicillamine could increase the therapeutic efficacy of platinum drugs in oxaliplatin resistant tumors, especially in resistant phenotype with downexpression of hCtrl and overexpression of ATP7A. Penicillamine 96-111 ATPase copper transporting alpha Homo sapiens 87-92 25801007-11 2015 Taken together, this study provides insight into that the co-manipulation of hCtrl and ATP7A by D-penicillamine could increase the therapeutic efficacy of platinum drugs in oxaliplatin resistant tumors, especially in resistant phenotype with downexpression of hCtrl and overexpression of ATP7A. Penicillamine 96-111 ATPase copper transporting alpha Homo sapiens 288-293 25064503-1 2015 In this contribution, a luminescent gold nanoclusters which were synthesized by bovine serum albumin as novel fluorescent probes were successfully utilized for the determination of D-penicillamine for the first time. Penicillamine 181-196 albumin Homo sapiens 87-100